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CHAPTER I: 
 
INTRODUCTION 
 
Lung Cancer 
Lung cancer is the leading cause of cancer-related mortality in the U.S. In 2015, over 220,000 
new diagnoses are expected as well as 155,000 lung cancer deaths, representing over a quarter of all 
deaths due to cancer (Siegel et al., 2015). The overall five-year-survival rate of a lung cancer diagnosis is 
17.8% (Howlader et al., 2015), which is largely due to lack of early detection methods and lack of 
effective therapy for long-term survival. The majority of lung cancer patients present with locally 
advanced or metastatic disease at diagnosis (Howlader et al., 2015). Standard therapy for patients with 
advanced disease includes non-specific cytotoxic chemotherapy or, for patients with specific genetic 
alterations, targeted therapies. The five-year-survival rate of patients diagnosed with advanced disease is 
less than 5% (Howlader et al., 2015). Attempts to define methods and strategies for earlier lung cancer 
detection have demonstrated that low-dose spiral computed tomography (CT) screening can reduce lung 
cancer deaths by up to 20% in adults at high risk for developing lung cancer (The National Lung 
Screening Trial Research Team, 2011), showing promise for improving survival rates. However, the 
recurrence rate is high, even with early diagnosis. Currently, only about 15% of patients present with 
localized tumors at diagnosis. Standard therapy for patients diagnosed with a localized tumor is surgical 
resection with adjuvant chemotherapy, and the five-year-survival rate is 54% (Howlader et al., 2015). 
The leading risk factor for developing lung cancer is smoking, and lung cancer risk increases with 
both smoking amount and duration. Globally, smoking accounts for 80% of the lung cancer burden in 
males and at least 50% of the burden in females (Ezzati and Lopez, 2003). In most Western countries, 
including many European countries, North America, and Australia, lung cancer death rates are declining 
due to increased awareness of smoking health hazards and reduced tobacco use (Bray and Weiderpass, 
2009; Jemal et al., 2011, 2008; Siegel et al., 2015). In contrast, lung cancer rates are rising in countries in 
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Asia and Africa, where the tobacco epidemic emerged more recently and smoking prevalence continues 
to increase or remains stable. In the U.S., temporal differences in lung cancer incidence exist between 
men and women because of historical differences in tobacco use between sexes, with smoking becoming 
popular among women decades later than men, resulting in a delayed peak in lung cancer incidence in 
women (Jemal et al., 2008). Even though lung cancer is primarily thought of as a smoking-related disease, 
approximately 15% of lung cancers in the U.S. arise in never-smokers (Samet et al., 2009), and 50% of 
women and 20% of men worldwide who develop lung cancer are never-smokers (Ezzati and Lopez, 
2003). Additional risk factors for developing lung cancer include secondhand smoke, which increases the 
risk of developing lung cancer by up to 25% (Stayner et al., 2007; Taylor et al., 2007), radon, asbestos, 
and other environmental exposures (Samet et al., 2009). 
Histologically, lung cancer can be broadly divided into small-cell lung cancer (SCLC) and non-
small-cell lung cancer (NSCLC). SCLC comprises about 15% of lung cancer diagnoses and is a very 
aggressive form of lung cancer, arising from neuroendocrine cells. NSCLC comprises approximately 85% 
of diagnosed lung cancers and can be further divided into three main histological subtypes--
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (Howlader et al., 2015). 
Adenocarcinomas have glandular histology and are typically found in the periphery of the lung, arising 
from the bronchial, bronchiolar, or alveolar epithelium. In contrast, squamous cell carcinomas are 
characterized by squamous differentiation, arising from the pseudostratified columnar epithelium of the 
trachea and upper airways. Large cell carcinomas are diagnosed by exclusion if cells do not appear 
glandular or squamous (Davidson et al., 2013), although it is unclear if large cell carcinomas are 
genetically distinct from squamous cell carcinomas or adenocarcinomas. 
 
Lung Adenocarcinoma 
Lung adenocarcinoma is the most prevalent subtype of NSCLC, accounting for more than 40% of 
all lung cancers (Howlader et al., 2015). The earliest precursor of adenocarcinoma is thought to be an 
atypical adenomatous hyperplasia (AAH), a pre-invasive lesion that is characterized by proliferation of 
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mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls or respiratory 
bronchioles (Kitamura et al., 1999; Mori et al., 2001). Adenocarcinoma in situ is a more advanced pre-
invasive lesion defined as a localized small adenocarcinoma with growth restricted to neoplastic cells 
along pre-existing alveolar structures and lacking stromal, vascular, or pleural invasion (Travis et al., 
2011). A minimally invasive adenocarcinoma (MIA) is a small adenocarcinoma with growth primarily 
along pre-existing alveolar structures and ≤5 mm invasion at any invasive focus. If the tumor invades 
lymphatics, blood vessels, or pleura or has an invasive protrusion >5 mm, the tumor is classified as an 
invasive adenocarcinoma (Travis et al., 2011).  
The precursor cell for lung adenocarcinoma tumors remains a subject of controversy, with 
different studies implicating type II pneumocytes (Desai et al., 2014; Lin et al., 2012; Mainardi et al., 
2014; Sutherland et al., 2014; Xu et al., 2012), Clara cells (Cho et al., 2011; Sutherland et al., 2014), and 
bronchoalveolar stem cells (Jackson et al., 2001; Kim et al., 2005) as the originating cell type. Alveolar 
type II cells are identified by expression of surfactant protein-C (SPC) and are able to repopulate the 
alveolar epithelium after injury (Adamson and Bowden, 1974; Evans et al., 1975). Clara cells are non-
ciliated bronchial epithelial cells that similarly have the capacity to serve as progenitors for the 
bronchiolar epithelium in response to injury and are identified by expression of Clara cell secretory 
protein (CCSP) (Giangreco et al., 2002; Hong et al., 2001). In mice, bronchoalveolar stem cells have been 
described that express Clara (CCSP) and type II (SPC) cell markers and reside at the bronchoalveolar duct 
junction (Jackson et al., 2001; Kim et al., 2005). Early hyperplastic lesions expressing both CCSP and 
SPC have been observed (Jackson et al., 2001), suggesting that these lesions arose from bronchoalveolar 
stem cells. In vivo studies in which oncogenic mutations were expressed in individual lung epithelial cell 
types have indicated that hyperplasias and benign adenomas can originate in Clara cells and 
bronchoalveolar stem cells but only type II cells are capable of producing malignant adenocarcinomas 
(Desai et al., 2014; Lin et al., 2012; Mainardi et al., 2014; Xu et al., 2012). However, lineage tracing 
studies revealed that adenocarcinomas can arise from both type II cells as well as a subset of Clara cells 
and suggested that CCSP+SPC- cells can trans-differentiate to CCSP-SPC+ cells during the course of 
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tumorigenesis (Sutherland et al., 2014), potentially explaining the appearance of CCSP+SPC+ 
hyperplastic lesions. 
In the past decade, researchers have moved beyond classifying tumors simply based on histology 
and have begun to further define lung adenocarcinoma subsets based on recurrent “driver mutations” in 
oncogenic genes. A “driver mutation” causes constitutive activation of the mutant signaling molecule, 
which initiates and sustains tumorigenesis. Multiple driver mutations are rarely found in the same tumor. 
The classification of tumors based on driver mutations enables a more precise identification of tumor 
subsets that respond to certain therapies and defines critical pathways in these tumors that can be targeted 
directly or indirectly to inhibit tumorigenesis.  
 The most common driver mutations in lung adenocarcinomas are Kirsten rat sarcoma viral 
oncogene homolog (KRAS) mutations, which are found in greater than 30% of lung adenocarcinoma 
tumors and are associated with poor prognosis and resistance to therapy (Herbst et al., 2008). KRAS is a 
small GTPase protein that cycles between a GDP-bound inactive state and a GTP-bound active state, 
linking extracellular signals transduced through membrane receptors to intracellular signaling pathways. 
Oncogenic mutations in KRAS most commonly occur in codons 12, 13, and 61. These mutations decrease 
the binding affinity of KRAS for its GTPase-activating protein (Trahey and McCormick, 1987), resulting 
in sustained KRAS activation and maintenance of signaling through downstream pathways involved in 
many processes known to promote tumorigenesis, including survival, proliferation, migration, and 
invasion. Even though KRAS is one of the most frequently mutated genes in a variety of cancers, no 
targeted therapies exist to treat patients with KRAS-mutant tumors.  
 While mutations in KRAS show a strong association with smoking, mutations in the epidermal 
growth factor receptor (EGFR) are more commonly found in non-smokers (Ahrendt et al., 2001; 
Husgafvel-Pursiainen et al., 1993; Rosell et al., 2009). EGFR is a receptor tyrosine kinase that signals 
through KRAS, resulting in activation of many of the same downstream pathways. EGFR mutations 
occur in approximately 15% of all lung adenocarcinomas (Rosell et al., 2009) and in about 50% of 
adenocarcinomas from patients of Asian descent (Shi et al., 2014), with the most common mutations 
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being exon 19 deletions and the exon 21 L858R point mutation (Li et al., 2008; Rosell et al., 2009). 
Mutations in EGFR destabilize the auto-inhibitory conformation of the kinase domain, resulting in 
constitutive kinase activation as well as constitutive activation of downstream signaling pathways (Yun et 
al., 2007), such as ERK, PI3K/Akt, and JAK/STAT. While targeted therapies have been developed to 
treat EGFR-mutant tumors, patient survival has only been modestly impacted because the tumors 
eventually become resistant, resulting in disease progression. The most common resistance mechanism to 
the first generation tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib is a T790M mutation in the 
receptor’s kinase domain, which increases its affinity for ATP (Pao et al., 2005; Yun et al., 2008). This 
finding has prompted the development of mutation-specific irreversible inhibitors, AZD9291 and 
rociletinib, which have shown therapeutic benefit in patients with T790M lung cancer (Jänne et al., 2015; 
Sequist et al., 2015). However, these patients also ultimately develop resistance. 
 
Inflammation in Cancer 
 In the 19th century, Rudolf Virchow first proposed a connection between inflammation and 
cancer. A role for inflammation in tumorigenesis is now generally accepted, with inflammation thought to 
impact every step of tumorigenesis from tumor initiation to metastasis, modulating tumor progression 
through pro- or anti-tumorigenic effects. Early neoplastic lesions are hypothesized to undergo 
immunoediting during which transformed cells are “eliminated” by the immune system, but rare tumor 
cell variants may survive (Schreiber et al., 2011). These remaining cells enter into “equilibrium,” where 
the immune system keeps them essentially dormant, but eventually these residual cells may “escape” by 
evading immune destruction or acquiring the capability to establish an immunosuppressive 
microenvironment. In tumors, anti-tumorigenic and pro-tumorigenic inflammatory signals coexist, 
competing for dominance throughout tumor development. Ultimately, the expression of various immune 
modulators and mediators as well as the presence and activation state of different inflammatory cell types 
dictate whether the inflammatory microenvironment is overall pro-tumorigenic or anti-tumorigenic 
(Grivennikov et al., 2010).  
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Current hypotheses suggest that inflammation and cancer can be linked through extrinsic or 
intrinsic inflammatory pathways (Figure 1) (Mantovani et al., 2008). The extrinsic inflammatory pathway  
is driven by a pre-existing chronic inflammatory condition that enhances cancer risk, and around 20% of 
cancers fall into this category of being related to chronic inflammation (Crusz and Balkwill, 2015). 
However, inflammatory cells and immune mediators are found in most, if not all, tumors, even those 
arising independently of a chronic inflammatory condition. In these tumors, intrinsic inflammation is 
driven by genetic alterations (such as an oncogenic mutation) that activate inflammatory signaling 
pathways resulting in production of extracellular mediators that recruit and/or polarize inflammatory cells 
(Mantovani et al., 2008). Thus, cancer can cause inflammation in the absence of a pre-existing 
inflammatory condition.  
The intimate association between cancer and inflammation has led to further investigations of 
their relationships with the goal of developing new therapeutic approaches for cancer treatment that target 
immune cells and mediators. A variety of different inflammatory cells have been implicated in 
carcinogenesis, including macrophages, immature monocytes, myeloid-derived suppressor cells, T cells, 
B cells, neutrophils, dendritic cells, eosinophils, and natural killer cells, and within some of these different 
immune cell populations, phenotypic subsets exist that have distinct effects on tumor development and 
progression. Additionally, the impact of inflammatory cells on tumorigenesis can be dependent on the 
specific organ and even cell type in which a tumor arises. Macrophages, neutrophils, and T cells are the 
most studied inflammatory cell types in the context of cancer, and a variety of therapies have been 
developed to target these cells and their mediators. 
Macrophages are the most abundant immune cell population in the lung and have been shown to 
promote both early and late stages of lung tumorigenesis (Zaynagetdinov et al., 2011a). Macrophages 
exist to phagocytose debris, pathogens, and dead/dying cells, as well as to release cytokines and 
chemokines regulating inflammation. Macrophages do not represent a single uniform cell type but, 
instead, are a heterogeneous population that can exhibit plasticity depending on microenvironmental cues. 
The two extremes of the macrophage phenotypic spectrum are the anti- tumorigenic M1 and the pro- 
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Figure 1:  Inflammation and cancer can be linked through extrinsic or intrinsic 
inflammatory pathways.  
Reprinted by permission from Macmillan Publishers Ltd: Nature (Mantovani, A., P. Allavena, A. Sica, and F. 
Balkwill. Cancer-related inflammation. 454(7203): 436–444), copyright (2008). 
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tumorigenic M2. M1 macrophages promote an anti-tumor response by presenting tumor-associated 
antigen to T cells and releasing pro-inflammatory cytokines, leading to tumor cell elimination. In contrast, 
M2 macrophages support tumorigenesis by suppressing anti-tumor immune responses, stimulating 
angiogenesis and lymphangiogenesis, and promoting tumor cell proliferation, invasion, and metastasis. In 
vivo studies have shown that a shift from an M1 to an M2 macrophage population occurs during the 
course of lung carcinogenesis (Redente et al., 2007). A number of factors produced by tumors such as 
extracellular matrix components, cytokines, and chemokines, including macrophage chemoattractants 
MCP-1/CCL2 and M-CSF/CSF1, can promote M2-skewing of the macrophage phenotype (Fridlender et 
al., 2011; Martinez et al., 2006; Roca et al., 2009; Sica and Mantovani, 2012). Current therapies in 
clinical trials that target macrophages or macrophage-associated factors include CSF1 receptor 
antagonists, anti-CCL2 monoclonal antibodies, and trabectedin, a chemotherapeutic agent that causes 
macrophage toxicity leading to reduced macrophages in tumor specimens (Crusz and Balkwill, 2015; 
Germano et al., 2013). 
 In lung cancer, neutrophil influx is associated with a poor prognosis (Bellocq et al., 1998). 
Neutrophils are the most common leukocyte in the bloodstream and function to protect the host from 
invading organisms by engulfing pathogens and, in instances of severe inflammation, secreting reactive 
oxygen species (ROS) and a variety of proteases. Neutrophils primarily exert their influence on tumors 
through production of ROS and proteases, although they can produce some cytokines and growth factors. 
Specifically in lung cancer, the neutrophil-derived protease neutrophil elastase promotes proliferation of 
tumors cells (Houghton et al., 2010), and in other cancers, neutrophils have been shown to enhance 
angiogenesis through production of matrix metalloproteinase-9 (Nozawa et al., 2006) and promote 
invasion and migration of tumor cells via hepatocyte growth factor and oncostatin M (Imai et al., 2005; 
Queen et al., 2005). ROS production by neutrophils can cause DNA damage, resulting in tumor 
promoting genotoxic effects (Sandhu et al., 2000), but ROS can also cause cytotoxic cell death of tumor 
cells (Dallegri et al., 1991). Similar to macrophages, some evidence suggests that neutrophils may exhibit 
phenotypic plasticity resulting in pro- and anti-tumorigenic N1 and N2 neutrophil populations (Fridlender 
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et al., 2009), although these phenotypes in neutrophils are not as well-described as in macrophages. 
Neutrophils are recruited by tumors and other cells in the tumor microenvironment primarily, but not 
exclusively, by CXC chemokines, including CXCL8/IL-8 or its murine homologs KC and MIP-2 (Ji et 
al., 2006). Reparixin, an inhibitor for the IL-8 receptors CXCR1/2 that reduces neutrophil chemotaxis 
(Zarbock et al., 2008), is currently being tested in clinical trials (Crusz and Balkwill, 2015).  
 Many different T cell subsets have been identified, but the T cell populations that have been best 
described in the context of cancer are CD4+ and CD8+ T cells and T regulatory cells. T cells function in 
the adaptive immune response, responding to specific antigens through T cell receptor-mediated 
recognition of peptides displayed by antigen presenting cells. Activation of T cells by antigen results in 
proliferation and migration to affected tissue. Cytotoxic CD8+ T cells are capable of direct lysis of 
malignant cells bearing the recognized antigen, while CD4+ helper T cells produce cytokines resulting in 
enhanced CD8+ T cell function and stimulation of other immune cell types. In contrast, T regulatory cells 
can suppress immune responses, hampering CD8+ T cell function by preventing activated T cell 
proliferation and maintaining T-cell tolerance to antigens (Woo et al., 2002). In lung tumors, increased T 
regulatory cell numbers have been observed (Woo et al., 2001). T cell-related treatments for cancer have 
mainly focused on re-activating T cell-mediated immunity through inhibition of PD-1/PD-L1 and CTLA-
4 signaling. PD-1 expression on CD8+ effector T cells indicates T cell unresponsiveness or exhaustion, 
and increased expression of PD-1 has been observed on tumor-infiltrating CD8+ T cells in NSCLC 
(Zhang et al., 2010). The primary ligand for PD-1, PD-L1, is expressed on a variety of immune cells and 
can also be expressed by tumors, limiting the anti-tumor immune response. In lung cancer, high levels of 
PD-L1 expression is a poor prognostic factor (Mu et al., 2011). In 2015, clinical trials testing two PD-1 
monoclonal antibodies, nivolumab and pembrolizumab (Borghaei et al., 2015; Garon et al., 2015), 
demonstrated therapeutic efficacy and received FDA approval for treatment of patients with NSCLC. 
Similarly, CTLA-4 is a negative regulator of T-cell-mediated immunity expressed on both CD4+ and 
CD8+ T cells, and ipilimumab, a monoclonal antibody targeting CTLA-4, led to increased progression 
free survival in a phase II clinical trial in NSCLC patients (Lynch et al., 2012).  
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NF-κB Signaling 
Nuclear factor κ-light chain enhancer of activated B cells (NF-κB) is a central mediator of the 
inflammatory response, and, in tumors, is thought to be a key signaling pathway involved in intrinsic 
inflammation. The NF-κB transcription factor regulates genes involved in a variety of processes in 
addition to inflammation, including cytokines, chemokines, receptors, adhesion molecules, and enzymes, 
as well as cell cycle, apoptosis, and survival regulators. Recent studies have suggested that the NF-κB 
signaling pathway is critical for lung tumorigenesis, making investigations of the mechanisms and 
mediators of NF-κB’s effect important for understanding lung tumor biology as well as for the 
identification of potential therapeutic targets. 
The NF-κB transcription factor family contains 5 members (p105/p50, p100/p52, p65/RelA, 
RelB, c-Rel), which share an N-terminal Rel homology domain responsible for DNA binding and 
dimerization. In addition, all of the NF-κB family members except for p50 and p52 contain a 
transactivation domain, suggesting that p50 and p52 are poor transcription factors on their own. In resting 
cells, the NF-κB family members exist as homo- or heterodimers sequestered in the cytoplasm by 
inhibitory molecules or IκBs. Precursor proteins p105 and p100 also contain C-terminal IκB-like domains 
that must undergo proteasomal processing to liberate the active transcription factors p50 and p52, 
respectively. When NF-κB is activated, the IκBs are phosphorylated and degraded. The NF-κB homo- or 
heterodimers are then released to bind κB enhancer motifs found in promoters and introns of target genes 
and regulate transcription through the recruitment of co-activators and co-repressors. The consensus NF-
κB binding sequence is 5’-GGGRN(Y)YYCC-3’, where R is a purine, Y is a pyrimidine, and N is any 
nucleotide, but NF-κB dimers can also bind to DNA sequences that lack a κB consensus binding site 
(Hoffmann, 2006; Siggers et al., 2011; Wong et al., 2011; Zhao et al., 2014). NF-κB activation can occur 
through either the canonical (classical) or the non-canonical (alternative) pathway (Figure 2). The net 
effect of NF-κB activation, in terms of gene expression changes, is dependent upon the specific cell type, 
activating signals, and NF-κB dimer composition.  
Canonical NF-κB signaling is highly dynamic and subject to tight regulation, as one of the targets 
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Figure 2:  Schematic of canonical and non-canonical NF-κB signaling pathways.  
Adapted by permission from Macmillan Publishers Ltd: Cell Research (Sun, S. Non-canonical NF-κB 
signaling pathway. 21(1): 71–85), copyright (2010). 
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of canonical pathway activation is its inhibitor, inhibitor of κBα (IκBα) (Brown et al., 1993). The 
canonical pathway is activated by a variety of stimuli including cytokine receptors, pattern-recognition 
receptors, and oncogenic mutations. When the canonical NF-κB signaling pathway is activated, a 
heterotrimeric IκB kinase (IKK) complex consisting of two kinases, IKKα and IKKβ, and a regulatory 
subunit, NF-κB essential modulator (NEMO)/IKKγ, becomes activated, with canonical pathway signaling 
being dependent on IKKβ and NEMO (Mercurio et al., 1997; Rothwarf et al., 1998; Woronicz et al., 
1997; Yamaoka et al., 1998). IKKβ phosphorylates IκBα on N-terminal serines (Ser32/36) (Chen et al., 
1996). This phosphorylation recruits the E3 ubiquitin ligase SCF/βTRCP, marking IκBα through K48-
linked polyubiquitination for degradation via the 26S proteasome (Kanarek and Ben-Neriah, 2012). 
Ubiquitination and degradation of IκBα exposes a nuclear localization sequence on the NF-κB dimers, 
enabling them to translocate into the nucleus. Canonical pathway activation is associated with nuclear 
localization of the prototypic NF-κB heterodimer made up of RelA/p65, which contains a strong 
transcriptional activation region, and p50. Canonical pathway activation can also be associated with 
heterodimers containing c-Rel, although c-Rel is primarily expressed in B- and T-lymphocytes (Gilmore 
and Gerondakis, 2011).  
In contrast, non-canonical pathway activation is significantly slower than canonical pathway 
activation and is long-lasting and steady, seemingly lacking strong negative feedback mechanisms and 
dynamic regulation (Hoffmann, 2006). The non-canonical pathway is activated by specific members of 
the TNF cytokine family, including lymphotoxin β (Dejardin et al., 2002) and CD40 ligand (Coope et al., 
2002), but it can also be activated by other stimuli, such as ROS (Iannetti et al., 2014) and STAT3 
(Nadiminty et al., 2006) signaling. Non-canonical pathway signaling is dependent on IKKα, which is 
activated by the upstream signaling kinase NF-κB-inducing kinase (NIK). When the non-canonical NF-
κB signaling pathway is activated, NIK activates IKKα through phosphorylation on Ser176 and 
phosphorylates p100 at Ser866 and Ser870 (Senftleben et al., 2001; Xiao et al., 2001). The activated 
IKKα is then able to phosphorylate p100 at Ser99, Ser108, Ser115, Ser123, and Ser872. These 
phosphorylations provide a signal recognized by the SCF/βTRCP ubiquitin ligase complex, resulting in 
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proteolytic processing of p100 by the 26S proteasome to remove its inhibitory C-terminal domain, also 
known as IκBδ (Xiao et al., 2004). The remaining 52 kDa polypeptide (p52) translocates into the nucleus 
to regulate transcription, typically as a heterodimer consisting of p52 and RelB.  
 
Canonical NF-κB Signaling in Cancer 
Activation of canonical NF-κB signaling has been observed in a variety of solid tumors including 
lung, breast, pancreatic, prostate, colon, as well as head and neck squamous cell carcinoma and is often 
associated with poor prognosis (Kojima et al., 2004; Ondrey et al., 1999; Sovak et al., 1997; Sweeney et 
al., 2004; Tang et al., 2006; Wang et al., 1999; Zhang et al., 2006). Specifically in the lung, bronchial 
biopsies from patients display increased nuclear staining for p65 (an indicator of canonical NF-κB 
activation) in adenocarcinoma tumors as well as in areas of dysplasia when compared to normal airway 
epithelium (Tichelaar et al., 2005). Others have shown high levels of nuclear p65 in lung cancer 
specimens relative to normal tissue, with increasing levels of nuclear p65 in advanced stage 
adenocarcinomas compared to early stage (Zhang et al., 2006). This same study also showed increased 
p65 staining in adenocarcinoma precursor lesions that progressed with increasing histological severity, 
suggesting that NF-κB signaling is activated very early in tumor formation. In mice, we previously 
reported that expression of a dominant inhibitor of the canonical NF-κB pathway in airway epithelial cells 
reduced chemical carcinogen-induced lung tumorigenesis by greater than 50% (Stathopoulos et al., 2007), 
demonstrating a requirement for NF-κB signaling in lung tumorigenesis. Conversely, activation of 
canonical NF-κB signaling in the airway epithelium using transgenic mice expressing a constitutively 
active IKKβ enhanced chemical carcinogen-induced lung tumorigenesis (Zaynagetdinov et al., 2011b), 
suggesting that modulation of epithelial canonical NF-κB signaling can affect disease severity. 
In lung cancer, canonical NF-κB activation has been shown to correlate with mutations in KRAS 
and EGFR (Tang et al., 2006). Studies in KRAS-mediated lung tumorigenesis as well as in mouse models 
of chemical carcinogen-induced lung cancer have demonstrated that NF-κB plays an important role in 
tumorigenesis (Bassères et al., 2010; Meylan et al., 2009; Stathopoulos et al., 2007; Zaynagetdinov et al., 
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2011b). Additionally, inhibition of canonical NF-κB signaling slows growth of established KRAS-driven 
tumors (Bassères et al., 2014; Meylan et al., 2009; Xue et al., 2011). EGFR activation has been shown to 
lead to canonical NF-κB activation in a variety of different tumor types (Alberti et al., 2012; De et al., 
2014; Sun and Carpenter, 1998), and in lung cancer, canonical NF-κB signaling has been shown to 
mediate resistance to both first generation and third generation EGFR TKIs (Bivona et al., 2011; Blakely 
et al., 2015; De et al., 2014; Galvani et al., 2015). However, the de novo importance of the NF-κB 
pathway during EGFR-driven lung tumorigenesis has not been investigated.  
Activation of KRAS and EGFR increases production of inflammatory cytokines, such as CXCL1, 
CXCL2, IL-1α, IL-1β, IL-6, and IL-11 in mice (Ancrile et al., 2007; Sparmann and Bar-Sagi, 2004; 
Wislez et al., 2006). Transgenic mice expressing KRASG12D specifically in the lung epithelium develop a 
profound inflammatory response characterized by increased macrophage and neutrophil infiltration (Ji et 
al., 2006). Similarly, in a different mouse model of KRAS-mediated lung tumorigenesis, macrophage 
infiltration was present even at the time of early hyperplastic lesion formation, and this infiltration 
increased with malignant progression (Wislez et al., 2005). Inflammatory cell infiltration has not 
previously been examined in mouse models of oncogenic EGFR expression in the lung, but in breast 
cancer, EGFR-positive tumors are associated with increased numbers of macrophages (Leek et al., 2000). 
Because of EGFR’s role in cytokine production and known associations between KRAS and 
inflammatory cell populations, EGFR mutations likely lead to changes in the tumor-associated 
inflammatory milieu. Whether oncogenic EGFR signaling causes recruitment of inflammatory cells via 
activation of NF-κB and what these inflammatory cell subpopulations are remains unknown.  
 
Non-Canonical NF-κB Signaling in Cancer 
Studies of non-canonical NF-κB signaling have largely focused on its role in cells of the 
hematopoietic lineage where it is important for the maturation and function of immune cells and the 
development of secondary lymphoid organs. Mice with global knockout of Nfkb2 (the gene for p100/p52) 
display defects in dendritic cell function, B-cell maturation, and T-cell responses and disorganization of 
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spleen and lymph node microarchitecture (Caamaño et al., 1998; Franzoso et al., 1998). Similarly, global 
knockout of the Relb gene leads to impaired cellular immunity, reduced dendritic cells, splenomegaly, 
and thymic atrophy (Weih et al., 1995). These effects are presumably due to the non-canonical pathway’s 
role in regulating expression of chemokine genes important for normal lymphoid organogenesis (Dejardin 
et al., 2002; Weih et al., 2001).  
In several hematopoietic malignancies including multiple myeloma, chronic lymphocytic 
leukemia, and B- and T-cell cutaneous lymphomas, chromosomal translocations in the Nfkb2 gene have 
been identified that truncate the C-terminus, removing the inhibitory domain (Migliazza et al., 1994; Neri 
et al., 1995, 1991). These truncated proteins localize in the nucleus, essentially leading to constitutively 
active p52 (Migliazza et al., 1994). Mice with global truncation of the Nfkb2 gene develop enlarged 
lymph nodes and hyperactive T cell responses, suggesting that p52 activation is playing a functional role 
in these diseases (Ishikawa et al., 1997).  
Compared to normal lung, high levels of p100/p52 and RelB have been observed in NSCLC 
tumors (Dimitrakopoulos et al., 2012). Additionally, increased activation of p52 has been observed in 
breast (Cogswell et al., 2000), prostate (Lessard et al., 2005; Seo et al., 2009), and pancreatic cancer 
(Wharry et al., 2009). Despite these observations, our understanding of the role of non-canonical pathway 
signaling in non-hematopoietic cells is limited, and whether non-canonical NF-κB signaling contributes to 
the pathogenesis of solid tumors has not been studied. 
Current evidence from in vitro and in vivo studies suggests that non-canonical NF-κB signaling 
may contribute to a number of critical factors affecting tumorigenesis. Tully, et al. demonstrated that 
lipopolysaccharide (LPS)-induced activation of inflammatory chemokines in airway epithelial cells is 
dependent upon non-canonical signaling components, supporting a role for non-canonical NF-κB 
signaling in paracrine signaling to inflammatory cells and implicating non-canonical NF-κB signaling as a 
regulator of inflammation in the lung (Tully et al., 2012). In fibroblasts, p52 and RelB protect against 
ROS-induced senescence in vitro by regulating cyclin-dependent kinase (CDK) 4 and CDK6 expression 
and antagonizing p53 function, suggesting that p52 may be important for promoting cell survival (Iannetti 
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et al., 2014). Several in vitro and in vivo studies have also implicated p52 in the regulation of 
proliferation. In androgen-dependent prostate cancer cells, p52 over-expression promotes proliferation in 
androgen-deprived conditions in vitro, protecting against cell cycle arrest and apoptosis through 
regulation of cyclin D1 (Nadiminty et al., 2008). In vivo, global p52 expression induced by deletion of the 
C-terminal inhibitory domain of p100 causes hyperplasia of the gastric epithelium (Ishikawa et al., 1997), 
although it is unclear whether this is a direct effect of p52 in the epithelium or the result of dysregulated 
immune responses. Transgenic mice that express p100 under the control of the β-lactoglobulin milk 
protein promoter develop ductal hyperplasia after multiple pregnancies (Connelly et al., 2007), again 
pointing toward a role for p52 in proliferation. Together these data suggest that non-canonical NF-κB 
signaling, and particularly p52, may be important in tumor development through regulation of chemokine 
genes and/or regulating cell proliferation/survival. 
 
Summary and Dissertation Goals 
 The high mortality rate of a lung cancer diagnosis underscores the need for a comprehensive 
understanding of signaling pathways contributing to lung carcinogenesis that can be targeted in 
combination with current treatment methods. A significant amount of data implicates canonical and non-
canonical NF-κB signaling as important factors in lung carcinogenesis. Several studies have demonstrated 
that canonical NF-κB signaling is a critical promoter of KRAS-driven lung tumors (Bassères et al., 2010; 
Meylan et al., 2009; Zaynagetdinov et al., 2011b). However, the mechanism(s) by which canonical NF-
κB promotes lung tumors is not well understood, and whether canonical NF-κB signaling is also 
important in lung tumors with driver mutations other than KRAS remains unknown. Increased expression 
of non-canonical pathway components have been observed in lung cancer (Dimitrakopoulos et al., 2012), 
yet little is known about the role of non-canonical NF-κB signaling in solid tumors. Since both NF-κB 
signaling pathways are important regulators of cytokine and chemokine production, we hypothesized that 
both canonical and non-canonical NF-κB signaling promote lung cancer via paracrine signaling to the 
inflammatory microenvironment. Acknowledging that these pathways regulate a variety of genes with 
17 
 
different functions, the overarching goal of this dissertation was to elucidate the primary mechanism(s) by 
which canonical and non-canonical NF-κB signaling participate in carcinogenesis. By characterizing the 
function(s) of these pathways, we aimed to identify critical mediators that could potentially serve as 
therapeutic targets for lung cancer patients. 
 In Chapter 2, we examined the requirement for canonical NF-κB signaling in EGFR-mutant lung 
tumors, demonstrating that inhibition of canonical NF-κB signaling reduces EGFR-mediated tumor 
formation in in vivo models of TKI-sensitive and TKI-resistant lung cancer. Since previous studies 
suggest that canonical NF-κB signaling is primarily important in EGFR-mutant lung tumors for 
promoting TKI resistance, these findings indicate that canonical NF-κB signaling plays a broader role in 
EGFR-mediated lung cancer. Additionally, these studies suggest that the primary mechanism by which 
canonical NF-κB signaling promotes EGFR-mediated lung tumorigenesis is through macrophage 
recruitment.  
 To study non-canonical NF-κB signaling, we generated a novel transgenic mouse model with 
inducible expression of p52 in the lung epithelium. In Chapter 3, we used this model to investigate the 
role of non-canonical NF-κB signaling in lung cancer. Surprisingly, p52 over-expression had no effect on 
inflammatory signaling but enhanced carcinogen-induced lung cancer by promoting proliferation through 
the regulation of cell cycle-associated genes, providing the first evidence that non-canonical NF-κB 
signaling plays a functional role in promoting lung carcinogenesis. Since others have shown that non-
canonical NF-κB signaling is activated by inflammatory stimuli and regulates cytokine genes, we 
examined the effect of in vivo p52 over-expression in the context of the inflammatory stimulus LPS in 
Chapter 4. In contrast to our findings in lung cancer, p52 over-expression in conjunction with LPS 
stimulation enhanced lung injury and epithelial cell apoptosis in vivo, and in vitro studies suggest that this 
apoptotic effect of p52 over-expression may be a more general response to acute cellular stress. Together, 
these studies demonstrate non-canonical NF-κB signaling as a regulator of proliferation/cell 
survival/apoptosis and implicate the non-canonical NF-κB pathway as a therapeutic target in the context 
of lung cancer and inflammatory diseases. 
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 This thesis describes the functions of canonical and non-canonical NF-κB signaling in lung 
carcinogenesis and suggests that the primary mechanism by which these pathways promote lung cancer 
may be different. The findings presented here advance our understanding of the complexity of these 
signaling pathways in different contexts and provide important insights for targeting them therapeutically.  
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CHAPTER II: 
 
EPITHELIAL CANONICAL NF-ΚB SIGNALING PROMOTES EGFR-DRIVEN LUNG 
CARCINOGENESIS VIA MACROPHAGE RECRUITMENT 
 
Rationale 
EGFR is a receptor tyrosine kinase that is mutated in approximately 15% of lung 
adenocarcinomas (Li et al., 2008; Rosell et al., 2009). Mutations in EGFR destabilize the auto-inhibitory 
conformation of the kinase domain (Yun et al., 2007), resulting in constitutive EGFR kinase activation as 
well as constitutive activation of downstream pathways, such as PI3K, MAPK, and JAK/STAT. Targeted 
therapies, such as TKIs, have been developed to treat lung cancer patients with EGFR-mutant tumors. 
However, these therapies have not significantly impacted overall patient survival because the tumors 
develop resistance, most commonly through the EGFR T790M mutation (Pao et al., 2005; Yun et al., 
2008). This lack of effective therapy for long-term survival demonstrates the need for identification of 
new pathways that can be targeted alone or in combination with current treatment methods.  
NF-κB is a transcription factor family that regulates genes involved in a variety of processes, 
including cytokines, chemokines, receptors, adhesion molecules, and enzymes, as well as cell cycle, 
apoptosis, and survival regulators. NF-κB family members exist as dimers sequestered in the cytoplasm 
by inhibitor molecules known as IκBs. When the pathway is activated, IκBs are phosphorylated and 
undergo rapid degradation by the proteasome, releasing NF-κB dimers to translocate into the nucleus and 
bind enhancer motifs found in the promoters and introns of target genes. NF-κB can be activated through 
either the canonical or non-canonical pathways. Canonical NF-κB signaling is associated with nuclear 
localization of a heterodimer consisting of p65 and p50, and non-canonical pathway signaling involves 
p52 and RelB. 
In lung cancer, canonical NF-κB activation is associated with a poor prognosis (Zhang et al., 
2006). High levels of nuclear p65 have been observed in lung cancer specimens relative to normal tissue, 
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with increasing levels of nuclear p65 in advanced stage adenocarcinomas (Tang et al., 2006). Lung 
adenocarcinoma precursor lesions also have increased nuclear p65 staining that progresses in intensity 
with increasing histological severity (Tang et al., 2006; Tichelaar et al., 2005), indicating that canonical 
NF-κB signaling is activated early in tumor formation. Canonical NF-κB activation in lung tumors is 
associated with mutations in common lung cancer driver genes, including KRAS and EGFR (Tang et al., 
2006). In KRAS-mediated lung tumorigenesis, as well as in mouse models of chemical carcinogen-
induced lung cancer, canonical NF-κB signaling plays an important role in tumor development (Bassères 
et al., 2010; Meylan et al., 2009; Stathopoulos et al., 2007; Zaynagetdinov et al., 2011b). EGFR signaling 
is known to activate canonical NF-κB in a variety of tumor types (Alberti et al., 2012; De et al., 2014), 
and canonical NF-κB signaling has been shown to facilitate resistance to EGFR inhibitor therapies in lung 
cancer (Bivona et al., 2011; Galvani et al., 2015). However, the importance of the canonical NF-κB 
signaling pathway during oncogenic EGFR-driven lung tumorigenesis has not been examined. 
To investigate the role of canonical NF-κB signaling in EGFR-mutant lung tumors, we inhibited 
epithelial canonical NF-κB in mouse models of TKI-sensitive and TKI-resistant EGFR-driven lung 
tumorigenesis by inducible expression of a dominant negative IκB (DN-IκB). In the setting of canonical 
NF-κB inhibition, we observed a dramatic reduction in lung tumor formation and a decrease in lung 
inflammation without changes in EGFR-regulated downstream signaling pathways. Together, these 
studies demonstrate that canonical NF-κB-dependent signaling is important for generating a pro-
tumorigenic inflammatory microenvironment in EGFR-mutant tumors. 
 
Materials and Methods 
 
Animal models 
All animal care and experimental procedures were approved and conducted according to 
guidelines of the Vanderbilt University Institutional Animal Care and Use Committee. (tet-O)7-EGFRL858R 
mice (Politi et al., 2006), (tet-O)7-EGFRL858R+T790M mice (Regales et al., 2007) (gifts from Dr. William 
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Pao, Vanderbilt University), (tet-O)7-IκBα-DN mice (Cheng et al., 2007), and CCSP-rtTA (Tichelaar et 
al., 2000) mice and genotyping procedures have all been previously described. Double transgenic 
EGFRL858R and EGFRL/T mice were generated by mating (tet-O)7-EGFRL858R or (tet-O)7-EGFRL858R+T790M 
mice to homozygous CCSP-reverse tetracycline (tet) transactivator (rtTA) mice. Triple transgenic 
EGFRL858R DN-IκB or EGFRL/T DN-IκB mice were generated by mating EGFRL858R or EGFRL/T mice to 
homozygous (tet-O)7-IκBα-DN mice. All mice were on a Friend leukemia virus B strain (FVB) 
background. Age- and sex-matched transgenic mice along with appropriate genotype-negative littermate 
controls (designated wild-type [WT]) were used in experiments. Transgene expression was activated by 
administering doxycycline (dox) at a concentration of 0.5 g/L for EGFRL858R experiments or 1 g/L for 
EGFRL/T experiments in 2% sucrose drinking water, and water was replaced twice weekly.  
For tissue harvest, lungs were lavaged as previously described (Zaynagetdinov et al., 2011b), and 
the left lung was tied off and frozen. The right lung was perfused and fixed by inflating with 10% neutral-
buffered formalin. Total and differential bronchoalveolar lavage (BAL) cell counts were determined as 
previously described (Stathopoulos et al., 2007). For survival analysis, EGFRL858R and EGFRL858R DN-
IκB mice were weighed on the day of dox initiation and at least twice weekly. Twenty percent weight loss 
was considered a mortality endpoint at which time mice were euthanized.  
 
Tumor histological analysis 
Hematoxylin and eosin (H&E) staining was performed on 5 µm sections for quantification of 
tumor burden. Three sections were analyzed per mouse, and each section was separated by 50 µm. For 
EGFRL858R tumor analysis, twenty non-overlapping 20x fields were scored on each section based on lesion 
formation using a scale of 0 to 4 (0 = normal, 1 = <10% of alveoli have hyperplastic proliferative lesions, 
2 = 10-50% of alveoli with proliferative lesions, 3 = <50% of alveoli with proliferative lesions, 4 = 
formation of tumor focus). For EGFRL/T tumor analysis, tumor area was measured and normalized to total 
lung area using Image-Pro Plus software (Media Cybernetics). 
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Immunostaining 
For CD68 immunostaining, lung sections were stained with a CD68 antibody (ab125212; 
Abcam), and positive cells were enumerated on twenty 40x fields. Mean scores were calculated for each 
animal.  
 
CT imaging 
CT images were acquired using a Bioscan NanoSPECT/CT system. All imaging was performed 
by the Vanderbilt University Institute of Imaging Science. 
 
RNA isolation, RT-PCR, and quantitative real-time PCR 
Total mRNA was isolated from lung tissue using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. Reverse transcriptase polymerase chain reaction (RT-PCR) was performed to 
measure EGFRL858R and EGFRL/T expression as previously described (Politi et al., 2006; Regales et al., 
2007). RT-PCR was also performed for DN-IκB and Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) using the following primers:  DN-IκB (F: CCTGGCTGTTGTCGAATACC; R: 
GGTGATGGTGATGATGACCGG), GAPDH (F: CCTGCACCACCAACTGCTTAG; R: 
GTGGATGCAGGGATGATGTTC). Quantitative real-time polymerase chain reaction (PCR) was 
performed using Sybr Green PCR Master Mix (Applied Biosystems) and the following primer sets:  
CCL2 (F: TTAAAAACCTGGATCGGAACCAA; R: GCATTAGCTTCAGATTTACGGGT), M-CSF (F: 
GTGTCAGAACACTGTAGCCAC; R: TCAAAGGCAATCTGGCATGAAG) (PrimerBank ID: 
166064045c1) (Spandidos et al., 2010, 2008; Wang and Seed, 2003), KC (F: 
CCGAAGTCATAGCCACACTCAA; R: GCAGTCTGTCTTCTTTCTCCGTTAC), MIP-2 (F: 
ACTCTCAAGGGCGGTCAAAA; R: GGCACATCAGGTACGATCCA), GAPDH (F: 
TGAGGACCAGGTTGTCTCCT; R: CCCTGTTGCTGTAGCCGTAT). For each sample, expression was 
normalized to GAPDH. Threshold values greater than 33 were considered below the limit of detection. 
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Cell lines 
HBEC3-KT (WT) and HBEC3-KTGmSRZ (EGFRL858R-mutant) immortalized human bronchial 
epithelial cells (Ramirez et al., 2004; Sato et al., 2006) (gifts from Dr. John Minna, The University of 
Texas Southwestern Medical Center) were maintained at 37ºC 5% CO2 in Keratinocyte-SFM 
supplemented with epidermal growth factor 1-53 and bovine pituitary extract (Thermo Scientific). Cells 
were transfected with myc/His-IκB-DN pEF4 (Cheng et al., 2007) or empty vector (EV) pEF4 using 
Xfect transfection reagent (Clontech).  
 
Western blot analysis 
Whole lung lysates were prepared using RIPA buffer, separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and probed 
with the following antibodies:  p-Akt (Ser473) (4060; Cell Signaling), total Akt (9722; Cell Signaling), p-
ERK (T202/Y204) (9101; Cell Signaling), total ERK (9102; Cell Signaling), p-STAT3 (Y705) (9131; 
Cell Signaling), total STAT3 (9132; Cell Signaling), or β-actin (SAB2100037, Sigma). Nuclear and 
cytoplasmic protein fractions were prepared from immortalized human bronchial epithelial cells using the 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher). Western blots were probed 
using the following antibodies:  myc (M4439; Sigma), caspase-3 (9622; Cell Signaling), β-actin (A2066, 
Sigma), p65 (C-20, Santa Cruz), or TATA-binding protein (TBP) (N-12, Santa Cruz). Jurkat cell lysates 
treated with cytochrome c were included as a positive control for cleaved caspase-3 (Cell Signaling; 
9663). Immunodetection was performed using the corresponding AlexaFluor-conjugated antibodies and 
the Odyssey Infrared Imaging System (LI-COR Biosciences). All images were converted to grayscale.  
 
Flow cytometry 
Lung single-cell suspensions were generated and stained as previously described (Zaynagetdinov 
et al., 2011a, 2011b). To reduce non-specific staining, single-cell suspensions were incubated with Fc 
receptor block (BD Biosciences). For detection of T cell populations, cells were incubated with the 
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following antibodies:  CD3-PE-Cy7 (145-2C11) and CD8a-AF700 (53-6.7) from BioLegend, CD4-FITC 
(RM 4-5) from eBioscience, and CD45-AP-Cy7 (30-F11) from BD Biosciences. For detection of 
neutrophil populations, cells were incubated with CD11b-A450 (M1/70) and Ly6G-PerCP-Cy5.5 (1A8) 
from BD Biosciences and CD45-AP-Cy7. Dead cells were excluded using a Live/Dead Fixable Blue 
Dead Cell Stain Kit (Life Technologies). Cells were analyzed using a LSR II flow cytometer (BD 
Biosciences), and data analysis was performed using FlowJo software (Tree Star, Inc.). 
 
In vitro migration assays 
Mouse bone marrow neutrophils were isolated from WT FVB mice as described by others. 
(Boxio et al., 2004) Neutrophil chemotaxis was assessed using a modified Boyden chamber MBA 96 
(Neuroprobe) with a 3 µm pore size polycarbonate filter. (Sai et al., 2008) Cell-free BAL supernatant was 
diluted 1:1 with 0.2% bovine serum albumin (BSA)/RPMI serum-free and phenol red-free media (final 
BSA concentration of 0.1%) and placed in the bottom chamber as the chemoattractant. Each BAL sample 
was run in triplicate. 2x105 neutrophils in 0.1% BSA/RPMI were loaded into the top chamber and 
incubated for one hour at 37ºC, 5% CO2.  
Mouse bone marrow-derived macrophages were isolated from WT FVB mice and matured as 
described by others (Munder et al., 1971). Macrophage chemotaxis was assessed as for neutrophils with a 
5 µm pore size polycarbonate filter. 250 ug of whole lung lysates from 5 week dox EGFRL858R and 
EGFRL858R DN-IκB mice was diluted in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 1% fetal bovine serum (FBS) and placed in the bottom chamber as the chemoattractant. Each lysate 
was run in triplicate. 1.5x105 macrophages in DMEM supplemented with 1% FBS were loaded into the 
top chamber and incubated for 5.5 hours at 37ºC, 5% CO2. 
The trans-migrated cells were collected by centrifuging the 96 well plate, washed three times, and 
resuspended in 100 µL Hank’s Balanced Salt Solution for neutrophils or 100 µL phosphate-buffered 
saline (PBS) for macrophages. 60 µL 4-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside (NAG) 
solution (4mM NAG, 25mM citric acid, 25 mM sodium citrate, and 0.25% Triton X-100, pH 5.0) was 
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added to each well and incubated overnight at room temperature in the dark. 100 µL stop solution (50 
mM glycine and 5 mM EDTA, pH 10.4) was added to each well, and the absorbance was measured at 405 
nM.  
 
Neutrophil depletion 
For neutrophil depletion experiments, mice received either 100 µg of anti-Ly6G antibodies 
(Clone 1A8, BioLegend) or IgG2a isotype control antibodies (BioLegend) by intraperitoneal (IP) 
injection. Mice were injected on day 7, 9, 12, and 14 after dox initiation and twice weekly thereafter until 
they were sacrificed at day 35 of dox. Neutrophil depletion was confirmed by lung flow cytometry and 
Wright-Giemsa staining of peripheral blood smears at day 35 of dox, 2 days after the final antibody 
treatment. 
 
Clodronate macrophage depletion 
Clodronate (Sigma) or PBS-containing liposomes were prepared as previously described 
(Everhart et al., 2005). 100 µL of clodronate or control PBS lipsomes was delivered intratracheally (IT) 3 
days prior to dox initiation, on the day of dox initiation, and weekly thereafter until mice were harvested 
at day 35 of dox. For liposome delivery, mice were anesthetized and intubated with a 1-mL syringe with a 
6-mm-long, 22-gauge over-the-needle catheter (Abbocath-T; Venisystems). Macrophage depletion was 
confirmed by CD68 staining of lung sections at day 35 of dox, 3 days after the final liposome treatment. 
 
Protein array 
Whole lung lysates were prepared from EGFRL858R and EGFRL858R DN-IκB mice treated with dox 
for 2 weeks. To minimize the effects of mouse-to-mouse-variability, lysates were pooled from 3 mice for 
each sample, resulting in a total of 4 samples (2 EGFRL858R and 2 EGFRL858R DN-IκB). Cytokine 
expression was determined using the Mouse Inflammation Array (AAM-INF-G1; RayBiotech, Inc.), 
which measures 40 different inflammation-associated analytes, including BLC (CXCL13), CD30L 
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(TNFSF8), Eotaxin-1 (CCL11), Eotaxin-2 (CCL24), FasL (TNFSF6), Fractalkine (CX3CL1), G-CSF, 
GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-
17A, I-TAC (CXCL11), KC, Leptin, LIX, Lymphotactin, MCP-1 (CCL2), M-CSF, MIG (CXCL9), MIP-
1α (CCL3), MIP-1γ, RANTES (CCL5), SDF-1α (CXCL12α), I-309 (TCA-3/CCL1), TECK (CCL25), 
TIMP-1, TIMP-2, TNF-α, TNFRI (TNFRSF1A), and TNFRII (TNFRSF1B). 
 
Enzyme-linked immunosorbent assays (ELISAs) 
KC and MIP-2 (R&D Systems) were measured in cell-free BAL supernatants. ELISAs were 
performed according to manufacturer’s instructions. 
 
Statistics 
Data were analyzed using GraphPad Prism 5.0 software (GraphPad Software, Inc.). Unpaired 
student t-tests were performed for comparisons between two groups. To analyze differences among more 
than two groups, one-way ANOVA followed by a Tukey’s post-test was used. For the Kaplan-Meyer 
survival analysis, a log-rank test was employed. Values are presented as the mean ± standard error of the 
mean (SEM), and p≤0.05 was considered statistically significant. 
 
Results 
 
Inhibition of epithelial canonical NF-κB signaling reduces EGFRL858R-mediated lung tumorigenesis 
To investigate the requirement for epithelial canonical NF-κB signaling in EGFR-driven lung 
tumor formation, we developed a model in which canonical NF-κB signaling could be inhibited in vivo 
specifically in airway epithelial cells expressing oncogenic EGFR. In this model, transgenic mice harbor a 
dox-inducible human EGFRL858R construct and the CCSP promoter-driven reverse tetracycline 
transactivator (CCSP-rtTA; tet-O-EGFRL858R) so that EGFRL858R is expressed specifically in the airway 
epithelium when given dox (designated EGFRL858R mice) (Politi et al., 2006). To inhibit epithelial 
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canonical NF-κB signaling in the lungs of these mice, EGFRL858R mice were mated to transgenic mice that 
express a dox-inducible dominant negative IκBα (DN-IκB) (Cheng et al., 2007). This DN-IκB is unable to 
be phosphorylated and degraded, thereby blocking translocation of the NF-κB heterodimers into the 
nucleus and preventing target gene transcription. Upon dox administration, these triple transgenic mice 
(designated EGFRL858R DN-IκB mice) express EGFRL858R with simultaneous inhibition of canonical NF-
κB signaling in airway epithelial cells.  
To assess the effect of canonical NF-κB inhibition on EGFR-mediated tumor formation, mice 
were administered dox for 5 weeks, and tumor burden was assessed by histological scoring of lung 
sections. After 5 weeks of dox treatment, EGFRL858R DN-IκB mice demonstrated a marked decrease in 
lung tumor burden compared to EGFRL858R mice (Figure 3A, B). In addition, fewer tumors were observed 
on CT scan images from EGFRL858R DN-IκB mice compared to EGFRL858R mice (Figure 3C). Transgene 
expression was validated in these mice using RT-PCR to measure expression of human EGFRL858R as well 
as DN-IκB in the lungs of mice administered dox for 5 weeks (Figure 3D). To further investigate the 
impact of reduced tumor formation in EGFRL858R DN-IκB mice, we performed a survival analysis, which 
revealed that EGFRL858R DN-IκB mice had significantly prolonged survival compared to EGFRL858R mice 
following dox treatment (Figure 3E). Together, these data show that epithelial canonical NF-κB inhibition 
can reduce tumor burden and prolong survival, implicating canonical NF-κB signaling in the epithelium 
as a critical factor for EGFR-mediated tumorigenesis. 
 
Epithelial canonical NF-κB inhibition does not affect epithelial cell survival or activation of EGFR-
regulated signaling pathways 
To investigate the function of epithelial canonical NF-κB signaling in lung tumors, we tested 
whether canonical NF-κB inhibition results in apoptosis of lung epithelial cells expressing oncogenic 
EGFR. In in vitro studies, we transfected WT and EGFRL858R-expressing immortalized human bronchial 
epithelial cells (Ramirez et al., 2004; Sato et al., 2006) with control EV or a myc-tagged DN-IκB 
expression vector and isolated nuclear and cytoplasmic protein extracts. Successful transfection was  
Figure 3:  Epithelial canonical 
tumorigenesis.  
Epithelial NF-κB inhibition reduces EGFR
burden (A), representative photomicrographs of 
representative CT images (C) from 
(n=13-14 mice/group; *p<0.0001). White asterisk designates the heart in CT images.
EGFRL858R (hEGFR) and DN-IκB transgenes using mRNA isolated from lungs of 
and EGFRL858R DN-IκB mice administered
and EGFRL858R DN-IκB mice after dox admini
n=10; log rank test p=0.0028). 
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verified by western blotting for myc-tagged transgene (Figure 4A). Reduced nuclear p65 was observed in 
DN-IκB-transfected cells, indicating reduced canonical NF-κB activation (Figure 4A). However, no 
increase in cleaved caspase-3 was observed as a result of NF-κB inhibition (Figure 4A), suggesting that 
canonical NF-κB activity is not required for survival of EGFRL858R-expressing cells. To measure 
apoptosis in vivo, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
on lung sections from EGFRL858R and EGFRL858R DN-IκB mice treated with dox for 2 weeks (prior to 
appearance of tumors) and 5 weeks (when tumors were present). We observed no increase in TUNEL-
positive cells in the lungs of EGFRL858R DN-IκB lungs compared to EGFRL858R at either time point (data 
not shown). 
We also measured activation of key EGFR-regulated downstream signaling pathways on western 
blots from whole lung lysates obtained from mice treated with dox for 2 weeks. No changes in Akt, ERK, 
or STAT3 phosphorylation were observed (Figure 4B-E). In addition to examining whole lung lysates 
from mice administered dox for 2 weeks, western blotting was performed on lysates from an enriched 
lung epithelial cell population generated from lungs of mice administered dox for 5 weeks. Similarly, no 
changes in EGFR-regulated downstream signaling pathways were observed as a result of NF-κB 
inhibition in this enriched population (data not shown). Together, these data suggest that canonical NF-κB 
inhibition does not affect downstream EGFR pathway signaling in EGFR-mutant cells. 
 
Canonical NF-κB inhibition reduces macrophage and neutrophil influx into the lungs of mice 
expressing mutant EGFR 
Since NF-κB is a central mediator of the inflammatory response, we next evaluated the effects of 
canonical NF-κB inhibition on inflammatory cell recruitment in the lungs of mice expressing mutant 
EGFR. Total inflammatory cells were counted in BAL from EGFRL858R, EGFRL858R DN-IκB, DN-IκB 
(CCSP-rtTA; tet-O-IκBα-DN), and WT mice treated with dox for 2 or 5 weeks. Prior to tumor formation, 
a ≥3-fold increase in BAL inflammatory cells was observed in EGFRL858R mice administered dox for 2 
weeks compared to control groups, and this inflammatory cell influx was not present in EGFRL858R DN- 
Figure 4:  Canonical NF-
apoptosis or EGFR-regulated signaling pathways
(A) Western blot of cytoplasmic and nuclear protein extracts from WT and EGFR
immortalized human bronchial epithelial cells transfected with DN
empty vector. β-actin and TATA
controls, respectively. Western blot 
phospho-STAT3 (E) using lung lysates from EGFR
for 2 weeks. For densitometry, phospho
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IκB mice (Figure 5A). When tumors were present at 5 weeks of dox treatment, a ≥10-fold increase in 
inflammatory cells was observed in EGFRL858R mice compared to control groups (Figure 5A). This 
dramatic increase was abrogated by inhibition of NF-κB in the epithelium. Together, these data indicate 
that epithelial canonical NF-κB signaling is important for recruiting inflammatory cells in this model, 
even prior to tumor formation. 
To identify inflammatory cell subpopulations altered as a result of epithelial canonical NF-κB 
inhibition, we performed CD68 immunostaining and quantified CD68+ macrophages on lung sections 
from EGFRL858R and EGFRL858R DN-IκB mice treated with dox for 2 weeks or 5 weeks. At both time 
points, lungs from EGFRL858R DN-IκB mice contained fewer macrophages compared to EGFRL858R mice 
(Figure 5B, C). To analyze changes in other lung inflammatory cell populations, we performed flow 
cytometry on lung single cell suspensions generated from EGFRL858R, EGFRL858R DN-IκB, DN-IκB, and 
WT mice. In mice administered dox for 5 weeks, NF-κB inhibition led to reduced neutrophils 
(CD45+CD11b+Ly6G+) in the lungs (Figure 5D) but no differences in T lymphocyte populations (Figure 
5E). Together, these data demonstrate that canonical NF-κB inhibition results in reduced neutrophils 
when tumors are present and reduced macrophages throughout tumorigenesis.  
 
Canonical NF-κB inhibition decreases lung tumors in mice expressing a TKI-resistant EGFR 
mutation 
To assess whether epithelial canonical NF-κB inhibition affects lung tumor burden and 
inflammatory cell numbers in a TKI-resistant model of EGFR-mediated tumorigenesis, we used 
transgenic mice with dox-inducible expression of human EGFRL858R+T790M (CCSP-rtTA; tet-O-
EGFRL858R+T790M). Similar to the EGFRL858R model, these mice express EGFRL858R+T790M in the airway 
epithelium when given dox (designated EGFRL/T mice). However, the presence of the T790M mutation 
renders tumors in these mice insensitive to treatment with first generation TKIs erlotinib and gefitinib 
(Regales et al., 2007). To inhibit epithelial canonical NF-κB signaling in the lungs of these mice, EGFRL/T 
mice were mated to transgenic DN-IκB mice (designated EGFRL/T DN-IκB).  
Figure 5:  Inhibition of epithelial 
cells in the lung during carcinogenesis. 
(A) Total BAL inflammatory cell numbers from WT, 
administered dox for 2 weeks or 5 weeks (for 2 week n=6
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CD68 macrophage immunostaining of lu
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IκB, EGFRL858R, and EGFRL858R DN
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 To determine the effect of epithelial canonical NF-κB inhibition on EGFR TKI-resistant EGFRL/T 
tumors, mice were treated with dox for 8 weeks, and tumor burden was assessed histologically. Similar to 
the EGFRL858R model, EGFRL/T DN-IκB mice demonstrated a dramatic reduction in lung tumor burden 
compared to EGFRL/T mice (Figure 6A, B). RT-PCR for EGFR transgene expression verified that 
EGFRL/T DN-IκB mice expressed the EGFR transgene after 8 weeks of dox administration (Figure 6C). In 
addition to decreased tumor burden, EGFRL/T DN-IκB mice had significantly fewer inflammatory cells in 
BAL (Figure 6D). Inflammatory cell subpopulations were analyzed on BAL cytospins as well as by 
CD68 staining for macrophages on lung sections from EGFRL/T and EGFRL/T DN-IκB mice, revealing a 
significant reduction in macrophages and neutrophils when canonical NF-κB signaling was inhibited 
(Figure 6E-G). These data were consistent with our findings in the EGFRL858R model and suggest that 
epithelial NF-κB signaling functions similarly in EGFR TKI-sensitive and TKI-resistant tumors. 
 
Canonical NF-κB signaling promotes macrophage and neutrophil chemotaxis 
To investigate whether epithelial canonical NF-κB inhibition affects macrophage and neutrophil 
recruitment to the lungs, we measured chemotaxis induced by BAL fluid or lung lysates using a modified 
Boyden chamber assay. Significantly more neutrophils migrated toward BAL fluid from EGFRL858R mice 
than BAL fluid from EGFRL858R DN-IκB mice (Figure 7A). To identify canonical NF-κB-regulated 
mediator(s) responsible for neutrophil chemotaxis in the setting of EGFR-mutant lung tumors, we 
measured mRNA expression of neutrophil chemokines by quantitative real-time PCR in lungs of mice 
treated with dox for 5 weeks, the time point at which we observed a significant difference in lung 
neutrophil numbers between EGFRL858R and EGFRL858R DN-IκB mice. KC and MIP-2 mRNA levels were 
reduced in EGFRL858R DN-IκB lungs compared to EGFRL858R (Figure 7B). KC and MIP-2 protein was 
also reduced in BAL from EGFRL858R DN-IκB mice (Figure 7C), suggesting that canonical NF-κB 
signaling promotes neutrophil migration to the lungs through regulation of CXC chemokines. 
Similarly, more macrophages migrated toward lung lysates from EGFRL858R mice than from 
EGFRL858R DN-IκB mice (Figure 7D). By quantitative real-time PCR, we measured mRNA expression of 
Figure 6:  Canonical NF-κ
in the TKI-resistant EGFR
Histological quantitation of lung tumor burden (A) and representative 
sections (10x magnification) (B) from
mice/group; ***p<0.001). (C) RT
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and BAL inflammatory cell differentials (
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the macrophage chemokine CCL2 and M-CSF, but neither of these factors was significantly reduced in 
lungs of EGFRL858R DN-IκB mice after 2 weeks of dox treatment (Figure 7E). To look more broadly for 
differences in potential macrophage chemotactic factors, we analyzed protein expression of a panel of 
inflammatory mediators (including known macrophage chemoattractants) in lung lysates from EGFRL858R 
and EGFRL858R DN-IκB mice treated with dox for 2 weeks or 5 weeks by protein array (Figure 7F and 
data not shown). However, we observed no significant reduction in any of these factors in EGFRL858R DN-
IκB mice, suggesting that non-traditional or non-protein mediators may impact macrophage migration in 
this model. 
 
Macrophages promote EGFR-mediated lung tumorigenesis 
In both TKI-sensitive and TKI-resistant models of EGFR-mediated lung tumorigenesis, we 
identified increased neutrophils and macrophages in the lungs, and those inflammatory cell types were 
reduced in the setting of NF-κB inhibition, suggesting the importance of these cells for EGFR-driven lung 
cancer. Therefore, we next investigated whether neutrophils and/or macrophages contribute to EGFR-
mediated tumorigenesis. To determine whether neutrophils play a role in tumorigenesis in EGFRL858R 
mice, we used Ly6G antibodies to deplete neutrophils throughout tumorigenesis. Ly6G depletion 
antibodies or IgG isotype control antibodies were administered by IP injection to EGFRL858R mice. 
Neutrophil depletion was verified by counting neutrophils in peripheral blood smears as well as by flow 
cytometry for neutrophils in lung single cell suspensions from mice on dox for 5 weeks (Figure 8A-B). 
Even though we observed successful neutrophil depletion, no difference in tumor burden was identified 
between EGFRL858R mice receiving Ly6G depletion antibodies and mice receiving isotype control 
antibodies (Figure 8C). These data indicate that neutrophils are not a critical cell type required for EGFR-
mediated tumor formation in this model and suggest that neutrophils are not the primary cell type through 
which epithelial NF-κB signaling impacts tumorigenesis.  
To test whether NF-κB–dependent recruitment of macrophages to the lungs is important for 
EGFR-mutant tumors, we depleted alveolar macrophages. Using a protocol that we previously developed 
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Figure 7:  Epithelial canonical NF-κB signaling promotes macrophage and 
neutrophil migration.  
(A) In vitro Boyden chamber chemotaxis assay for neutrophils using BAL fluid from EGFRL858R and 
EGFRL858R DN-IκB mice treated with dox for 5 weeks (n=8/group; ***p<0.001). B) Quantitative real-time 
PCR for KC and MIP-2 using mRNA from lungs of EGFRL858R and EGFRL858R DN-IκB mice administered 
dox for 5 weeks (n=5-9/group; *p<0.05; all EGFRL858R DN-IκB MIP-2 measurements below threshold). C) 
KC and MIP-2 ELISA measurements using BAL fluid from WT, DN-IκB, EGFRL858R, and EGFRL858R DN-
IκB mice treated with dox for 5 weeks (n=4-10 mice/group; *p<0.05, **p<0.01, ***p<0.001). (D) Boyden 
chamber chemotaxis assay for macrophages using lung lysates from EGFRL858R and EGFRL858R DN-IκB mice 
treated with dox for 5 weeks (n=5-8/group; **p<0.01). E) Quantitative real-time PCR for CCL2 and M-CSF 
using mRNA from lungs of EGFRL858R and EGFRL858R DN-IκB mice treated with dox for 2 weeks 
(n=4/group). (F) Select data from protein expression array for inflammatory mediators using whole lung 
lysates from EGFRL858R and EGFRL858R DN-IκB mice treated with dox for 2 weeks. 
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(Everhart et al., 2005; Zaynagetdinov et al., 2011a), macrophages were depleted by repeated dosing of 
liposomal clodronate, which causes selective macrophage apoptosis. Liposomal clodronate or control 
PBS liposomes were delivered IT to EGFRL858R mice weekly, beginning 3 days prior to starting dox 
treatment. CD68 immunostaining was performed on lung sections from mice treated with dox for 5 
weeks, verifying macrophage depletion (Figure 8D). After 5 weeks of dox administration, tumor burden 
was significantly reduced in EGFRL858R mice administered IT liposomal clodronate when compared to 
mice receiving PBS liposomes (Figure 8E), indicating that recruitment of macrophages is important for 
EGFR-mediated tumor formation. 
 
Discussion 
 These studies demonstrate that epithelial canonical NF-κB signaling promotes lung 
tumorigenesis, at least in part through recruitment of macrophages to the lungs. In transgenic mouse 
models of both EGFR TKI-sensitive and TKI-resistant lung tumorigenesis, epithelial canonical NF-κB 
inhibition reduced tumor burden. However, canonical NF-κB inhibition did not affect survival of EGFR-
mutant airway epithelial cells or alter activation of known EGFR-mediated signaling pathways. Instead, 
in the settings of both TKI-sensitive and TKI-resistant lung tumors, epithelial canonical NF-κB signaling 
was important for recruiting inflammatory cells to the lung, namely macrophages and neutrophils. In 
additional studies, we observed that neutrophil depletion did not impact EGFR-mediated tumorigenesis, 
but macrophages contributed to tumor formation. Taken together, these data suggest that classical NF-κB 
signaling functions primarily in a non-cell autonomous manner to promote EGFR-mediated lung 
tumorigenesis. 
In EGFR-mutant tumors, NF-κB signaling has been proposed as a common mechanism of TKI 
resistance (Bivona et al., 2011; Blakely et al., 2015; De et al., 2014; Galvani et al., 2015). De, et al. 
demonstrated that stimulation of NF-κB signaling in vitro enhanced resistance of lung cancer cells to 
erlotinib treatment (De et al., 2014). Furthermore, NF-κB inhibition in conjunction with erlotinib 
treatment has been shown to promote apoptosis of erlotinib-resistant lung cancer cells in vitro and reduce 
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Figure 8:  Macrophages promote EGFR-mediated lung tumorigenesis.  
Flow cytometry analysis of lung single cell suspensions (A) (n=4/group; *p<0.05), quantification of 
neutrophils as a percentage of total white blood cells in peripheral blood smears (B) (n=7/group; **p<0.01), 
and histological analysis of tumors (C) (n=11-14/group) from EGFRL858R mice administered dox for 5 weeks 
and treated with Ly6G depletion or IgG isotype control antibodies. Quantification of CD68 macrophage 
immunostaining (D) (n=3-5/group; *p<0.05) and histological analysis of tumors (E) (n=12-14/group; 
**p<0.01) on lung sections from EGFRL858R mice administered dox for 5 weeks and treated with PBS or 
clodronate liposomes. 
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tumor growth in xenograft models (Bivona et al., 2011; Blakely et al., 2015). More recently, NF-κB 
activation was shown to drive resistance to an analog of the selective EGFR-T790M inhibitor CO-1686 in 
T790M mutant cells (Galvani et al., 2015). While these prior studies indicate that NF-κB signaling 
supports resistance of EGFR-mutant tumors to TKIs, our findings indicate that NF-κB signaling plays a 
broader role in EGFR-driven lung carcinogenesis. 
Inflammation has been linked to cancer promotion through two pathways—the extrinsic pathway, 
characterized by a pre-existing inflammatory condition, and the intrinsic pathway, driven by oncogenic 
mutations that lead to an inflammatory response (Mantovani et al., 2008). In our transgenic mouse 
models, expression of oncogenic EGFR in the lungs led to a significant intrinsic inflammatory response 
that was dependent upon canonical NF-κB signaling. Similarly, transgenic mice with expression of 
oncogenic KRAS also exhibit an inflammatory influx, characterized by increased macrophages and 
neutrophils (Ji et al., 2006). Oncogenic KRAS has been shown to lead to activation of canonical NF-κB 
signaling (Bassères et al., 2010), and inhibition of canonical NF-κB signaling in KRAS-mutant tumors 
reduces tumor burden (Bassères et al., 2010; Meylan et al., 2009), suggesting that canonical NF-κB 
signaling may function similarly to promote intrinsic inflammation in both EGFR- and KRAS-mutant 
lung tumors. 
Even though we observed no effect on tumorigenesis after neutrophil depletion, neutrophils have 
been shown to contribute to carcinogenesis in other contexts. Neutrophils can produce a variety of growth 
factors, ROS, and proteases that promote tumor angiogenesis, proliferation, and invasion (Gregory and 
Houghton, 2011), and NF-κB signaling in tumors has been shown to regulate expression of chemokines 
leading to neutrophil recruitment (Sparmann and Bar-Sagi, 2004). In human lung cancer, neutrophil 
influx is associated with a poor prognosis (Bellocq et al., 1998), and in a transgenic mouse model of 
KRAS-driven lung cancer, depletion of neutrophil elastase caused significantly fewer lung tumors due to 
reduced tumor cell proliferation (Houghton et al., 2010). While we saw enhanced neutrophil recruitment 
in our EGFR-driven lung cancer models, this increase in neutrophils was modest compared to the increase 
in macrophages and was only observed at later time points, suggesting that the contributions of the 
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neutrophils to lung tumorigenesis in this model may have been overshadowed by the pro-tumorigenic 
effect of the macrophage influx. 
Our findings indicate that epithelial canonical NF-κB signaling recruits macrophages to promote 
lung carcinogenesis and suggest that therapeutic targeting of macrophages should be explored in EGFR-
mutant lung cancer. Although NF-κB regulates a variety of chemokines that promote macrophage 
recruitment, we did not observe changes in known macrophage chemokines upon NF-κB inhibition. 
Although it is possible that novel protein mediators induce macrophage recruitment in our models, we 
speculate that non-protein mediators may account for the NF-κB-dependent influx of macrophages in 
mice expressing mutant EGFR. For example, eicosanoids can be potent macrophage chemoattractants, 
and a variety of factors involved in eicosanoid synthesis are regulated by NF-κB signaling (Haribabu et 
al., 2000; Osma-Garcia et al., 2015). Future studies to identify the NF-κB-regulated mechanism of 
macrophage recruitment in the EGFRL858R and EGFRL/T lung cancer models may reveal additional 
potential therapeutic targets for development of novel treatment strategies for patients with EGFR-mutant 
lung cancers. 
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CHAPTER III: 
 
NON-CANONICAL NF-ΚB SIGNALING RESULTING FROM P52 EXPRESSION 
ENHANCES LUNG CANCER PROGRESSION THROUGH REGULATION OF CELL 
CYCLE GENES 
 
Parts of this chapter were originally published in The Journal of Immunology. Saxon JA, Cheng D-S, Han W, 
Polosukhin V, McLoed AG, Richmond BW, Gleaves LA, Tanjore H, Sherrill TP, Barham W, Yull FE, 
Blackwell TS. 2016. p52 over-expression increases epithelial apoptosis, enhances lung injury, and reduces 
survival after LPS treatment. J. Immunol. 196(4) 1891-1899. Copyright © 2016 The American Association of 
Immunologists, Inc. 
 
Rationale 
Lung cancer is the leading cause of cancer-related death in the U.S. In 2015, an estimated 
221,200 new lung cancer diagnoses are expected, representing 13 percent of all cancer diagnoses (Siegel 
et al., 2015). The five-year survival rate of a lung cancer diagnosis is less than 20 percent (Siegel et al., 
2015), emphasizing the need for a better understanding of tumor biology in the development of new 
therapeutic approaches. In addition, identification of biomarkers that improve prediction of outcomes 
beyond the current staging system would be useful for developing new treatment strategies.  
Numerous studies have demonstrated the critical role of epithelial NF-κB signaling in lung cancer 
(Bassères et al., 2010; Meylan et al., 2009; Stathopoulos et al., 2007). The NF-κB transcription factor 
family contains 5 members (p65/RelA, p52, p50, RelB, and c-Rel) and can be activated through either the 
canonical or non-canonical signaling pathways. Canonical pathway activation occurs when inhibitory 
IκBs are phosphorylated, releasing a p65/p50 heterodimer to translocate into the nucleus. Non-canonical 
NF-κB signaling hinges on proteolytic processing of p100 to p52, which removes an inhibitory C-
terminal domain. p52 is then able to enter the nucleus, typically as a heterodimer bound to RelB. In lung 
tumors, increased expression of components of both the canonical and non-canonical NF-κB signaling 
pathways has been observed (Dimitrakopoulos et al., 2012; Tang et al., 2006). However, studies of NF-
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κB in lung cancer have mainly focused on canonical pathway signaling, leaving the function of non-
canonical pathway activation in lung tumors uninvestigated.  
The majority of knowledge about the in vivo function of p100/p52 and non-canonical NF-κB 
signaling relates to its role in lymphoid development and hematopoietic disease. Mice with global 
knockout of the Nfkb2 gene, which encodes p100, demonstrate defective dendritic cell function, B-cell 
maturation, T-cell responses, and secondary lymphoid organ development (Caamaño et al., 1998; 
Franzoso et al., 1998), presumably due to p52’s role in regulating expression of chemokine genes 
important for normal lymphoid organogenesis (Dejardin et al., 2002). In several hematopoietic 
malignancies including multiple myeloma, chronic lymphocytic leukemia, and B- and T-cell cutaneous 
lymphomas, chromosomal translocations in the Nfkb2 gene, which encodes p100, have been identified 
that truncate the C-terminus, removing the inhibitory domain (Migliazza et al., 1994; Neri et al., 1995, 
1991). These truncated proteins localize in the nucleus, essentially leading to constitutively active p52 
(Migliazza et al., 1994). Mice with global truncation of the Nfkb2 gene develop enlarged lymph nodes and 
hyperactive T cell responses, providing some insight into the function of activated p52 in hematopoietic 
diseases (Ishikawa et al., 1997). However, these mice die prematurely due to significant gastric 
hyperplasia (Ishikawa et al., 1997), hinting that dysregulated p52 activation may play a role in epithelial 
cancers also.  
Increased activation of p52 has been observed in lung (Dimitrakopoulos et al., 2012), breast 
(Cogswell et al., 2000), prostate (Lessard et al., 2005; Seo et al., 2009), and pancreatic cancer (Wharry et 
al., 2009). However, studies on the effects of p52 activation in cancers of epithelial origin have been 
limited due lack of appropriate in vivo models. Here, we generated a novel transgenic mouse model with 
inducible expression of p52 specifically in airway epithelial cells (designated CCSP-p52) to investigate a 
potential role for p52 in lung tumorigenesis. Together, these studies define a role for p52 in lung 
tumorigenesis and identify a p52-associated gene network that is highly correlated with patient prognosis.  
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Materials and Methods 
 
Generation of CCSP-p52 mouse model 
The p52 cFlag pcDNA3 plasmid containing C-terminal FLAG-tagged murine p52 was a gift from 
Stephen Smale (Addgene plasmid #20019). This plasmid was digested first with HindIII followed by SacI 
digestion to obtain a fragment containing the FLAG-p52. The ends of this fragment were filled in before 
ligation into the EcoRV site of a modified pBluescript II SK expression vector, which contains a (tet-O)7-
CMV promoter consisting of seven copies of the tet operator DNA-binding sequence linked to a minimal 
CMV promoter together with bovine growth hormone poly-adenylation sequences to ensure transcript 
termination. The final plasmid ((tet-O)7-FLAG-p52-BGH.poly(A)) was verified by sequencing. To 
prevent basal leakiness, a construct expressing a tet-controlled transcriptional silencer (tTS) under control 
of the CCSP promoter (CCSP-tTS-hGH.poly(A)) was also included (Cheng et al., 2007; Zhu et al., 2001). 
The (tet-O)7-FLAG-p52 microinjection fragment was excised from the plasmid by digesting with AscI, 
resulting in a 2.1 kb fragment. The 5 kb CCSP-tTs fragment was excised using XhoI and NotI. Both 
constructs were purified with the GELase Agarose Gel-Digesting Preparation kit (Epicentre) following 
the manufacturer’s instructions. These constructs were co-injected at the Vanderbilt Transgenic 
Mouse/Embryonic Stem Cell Shared Resource to generate transgenic lines of FVB background mice with 
co-integration of both the CCSP-tTS and the (tet-O)7-FLAG-p52 transgenes. Genotyping of the founder 
animals was performed by Southern blot, and all subsequent genotyping was performed by PCR analysis. 
Primers used for PCR of the (tet-O)7-p52-FLAG are as follows: F: GACGCCATCCACGCTGTTTTG 
and R: AGGATAGGTCTTCCGGCCCTT. The product size is 322 bp. Primers used for PCR of the 
CCSP-tTS are as follows: F: GAGTTGGCAGCAGTTTCTCC and R: GAGCACAGCCACATCTTCAA. 
The product size is 472 bp. Four founder lines of CCSP-tTS/(tet-O)7-FLAG-p52 mice were mated with 
CCSP-rtTA homozygous mice (gift from Dr. J.A. Whitsett, University of Cincinnati, Cincinnati, OH) 
(Tichelaar et al., 2000) to obtain triple transgenic mice, which were designated CCSP-p52. CCSP-p52 
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mice generated from two separate founder lines of CCSP-tTS/(tet-O)7-FLAG-p52 mice were used for 
these studies.  
 
Animal experiments 
For urethane experiments, mice were placed on dox for 1 week prior to IP injection of urethane (1 
g/kg body weight; Sigma-Aldrich) and remained on dox until euthanized. For 6 month tumor 
experiments, mice received weekly IP injections of urethane for 4 weeks. At sacrifice, lungs were 
lavaged, and total and differential BAL cell counts were determined as previously described 
(Stathopoulos et al., 2007; Zaynagetdinov et al., 2011b). The left lung was tied off and frozen, and the 
right lung was perfused and fixed by inflating with 10% neutral-buffered formalin. All animal studies 
were approved and conducted according to the guidelines of the Vanderbilt University Institutional 
Animal Care and Use Committee.  
 
Generation of p52-overexpressing RLE-6TN cells 
Rat type II alveolar epithelial cell line RLE-6TN (ATCC) was maintained at 37ºC 5% CO2 in 
DMEM (Invitrogen) with 4.5 g/l glucose and 2mM L-glutamine, supplemented with 10% FBS, 100 
units/ml penicillin, and 100 µg/ml streptomycin. p52 expression construct p52 cFLAG pcDNA3 and 
control EV cFLAG pcDNA3 were gifts from Stephen Smale (Addgene plasmids #20019 and #20011). 
RLE-6TN parental cells (RLE-WT) were stably transfected with p52 cFLAG pcDNA3 (RLE-p52) or 
empty vector cFLAG pcDNA3 (RLE-EV) using Effectene transfection reagents (Qiagen) according to the 
manufacturer’s protocol, and G418-selected clones were pooled. To confirm transgene expression, the 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) were used to prepare nuclear 
protein from RLE-EV and RLE-p52 transfected cells that had undergone selection, and a western blot was 
performed and probed with antibodies as described for western blot analysis below.  
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Western blot analysis  
Nuclear protein was prepared from lung tissue and RLE-6TN cells using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific), separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and probed using the following antibodies:  FLAG (F3165, Sigma), p100/p52 
(4882, Cell Signaling), p65 (C-20, Santa Cruz), p50 (C-19, Santa Cruz), RelB (C-19, Santa Cruz), cRel 
(C, Santa Cruz), and TBP (N-12, Santa Cruz). Immunodetection was performed using the corresponding 
AlexaFluor-conjugated antibodies and the Odyssey Infrared Imaging System (LI-COR Biosciences). All 
images were converted to grayscale.  
 
Histology and immunostaining 
After fixation, lungs were embedded in paraffin, sectioned (5 µm), and H&E-stained for 
histological analysis and quantification of tumor burden. Three sections were analyzed per mouse, and 
each section was separated by 50 µm. Tumor area was measured using Image-Pro Plus software (Media 
Cybernetics), and tumor number was enumerated on each section. AAH lesions and tumor histology were 
assessed by a pathologist blinded to the experimental groups. Tumors were classified as adenomas (clear 
border), MIAs (border mostly defined with one invasive edge), and adenocarcinomas (no defined border). 
To evaluate transgene expression in CCSP-p52 mice, 5 µm lung sections were stained with an anti-FLAG 
antibody (600-403-383, Rockland). To assess p100/p52 expression in human lung adenocarcinomas, 
immunostaining using a p100/p52 antibody (C-5, Santa Cruz) was performed on a lung adenocarcinoma 
tissue microarray (TMA) with 106 tumor samples (spots) from 34 patients. p100/p52 staining of tumor 
spots was scored by two independent readers, including a pathologist. Scoring was performed as follows: 
0 = no staining; 1 = diffuse cytoplasmic staining, no nuclear staining; 2 = dark granular cytoplasmic 
staining, no nuclear; 3 = nuclear staining in <25% of tumor cells; 4 = nuclear staining in >25% of tumor 
cells. Each tumor had at least two spots on the TMA, and the mean score was calculated for each tumor 
based on the individual scores for each spot. 
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In vitro proliferation measurements 
RLE-EV and RLE-p52 cells were plated in 96 well plates for viability and 5-bromo-2'-
deoxyuridine (BrdU) incorporation measurements. 48 hours after plating, cells were incubated with BrdU 
for 4 hours, and BrdU incorporation was measured using the chemiluminescent BrdU Cell Proliferation 
ELISA (Roche). To ensure plating of equal numbers of cells, cell viability of RLE-EV and RLE-p52 cells 
was measured on the same day as a surrogate for cell number using the CellTiter-Glo Luminescent Cell 
Viability assay (Promega) according to the manufacturer’s protocol. 
 
Gene expression microarray analysis 
The RNeasy Mini kit (Qiagen) was used to isolate whole lung mRNA from CCSP-p52 and WT 
mice on dox for 1 week and mice on dox for 1 week 48 hours after IT LPS administration. To minimize 
the effects of mouse-to-mouse-variability, RNA was pooled from 3 mice for each sample, resulting in a 
total of 8 samples (2 WT dox only, 2 WT with LPS, 2 CCSP-p52 dox only, 2 CCSP-p52 with LPS). RNA 
quality control, hybridization to the Affymetrix Mouse Gene 1.0 ST array, and array scanning were 
performed by the Vanderbilt Technologies for Advanced Genomics (VANTAGE) Core. Expression data 
have been deposited in Gene Expression Omnibus (Accession # GSE71648). 
The Robust Multichip Average method (Bolstad et al., 2003) implemented in R package “oligo” 
(v1.28.3) (Carvalho and Irizarry, 2010) was employed to normalize imported raw data. Probe sets 
interrogating control, unmapped, or intron sequences were ignored, leaving 79% of probe sets for a 
differential expression analysis. Linear models and empirical Bayes methods implemented in R package 
“limma” (v3.20.8) (Smyth, 2005) were applied to estimate log fold changes (FCs) and p-values for the 
p52-vs-WT effect. Since samples with and without LPS stimulation were processed and microarray 
profiled at the same time, we assumed the random data variations were similar across all samples and 
built a linear model across the eight samples accounting for both p52 and LPS experimental factors 
(Smyth, 2004). The coefficient (estimated logFC) and p-value associated with the p52 factor were 
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retrieved for the selection of differentially expressed genes. When selecting top-ranking p52-induced 
genes, only probe sets mapping to known genes and having positive expression changes were considered. 
 
Quantitative PCR 
Quantitative real-time PCR was performed using Sybr Green PCR Master Mix (Applied 
Biosystems) and the following primer sets:  Ccna2 F: AAGAGAATGTCAACCCCGAAAAA; R: 
ACCCGTCGAGTCTTGAGCTT (PrimerBank ID: 161353443c1), Top2a F: 
CAACTGGAACATATACTGCTCCG; R: GGGTCCCTTTGTTTGTTATCAGC (PrimerBank ID: 
6755849a1), Ube2c F: CTCCGCCTTCCCTGAGTCA; R: GGTGCGTTGTAAGGGTAGCC 
(PrimerBank ID 21312888a1) and GAPDH (F: TGAGGACCAGGTTGTCTCCT R: 
CCCTGTTGCTGTAGCCGTAT) (Spandidos et al., 2010, 2008; Wang and Seed, 2003). Expression 
values were normalized to GAPDH using the ∆CT method. 
 
Human lung cancer expression data analysis 
Raw expression data for 513 lung adenocarcinoma patient samples, generated by The Cancer 
Genome Atlas (TCGA) project, were accessed from the ICGC data portal (https://dcc.icgc.org/; release 
17). The raw RSEM values (Li and Dewey, 2011) were multiplied by 106 to normalized values of 
Transcripts Per Million. Of these 513 samples, matched tumor samples and paracancerous normal 
samples were available for 54 patients. A paired t-test was performed for each gene, and the resultant p-
values were adjusted to false discovery rates (FDRs) using the Benjamini-Hochberg method (Benjamini 
and Hochberg, 1995).  
Of the 513 lung adenocarcinoma samples, 437 primary lung adenocarcinoma samples had 
accompanying survival outcome data. In each survival analysis, samples were divided into two groups of 
equal sizes (termed high-expression and low-expression groups) by considering the collective expression 
of p52-associated genes. R package “survival” (v2.37-7) (Therneau and Grambsch, 2000) was employed 
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to conduct survival analyses. In survival analyses, survival time values were truncated to 5 years (1825 
days) to reflect 5 year survival rates. 
 
Gene functional analysis 
Functions enriched within p52 associated genes were identified through a hypergeometric test 
with respect to Gene Ontology (GO) (Ashburner et al., 2000) terms, using R package GOstats (v1.7.4) 
(Falcon and Gentleman, 2007). For each GO term, genes from the reference set of whole human genome 
protein-coding genes and the concerned set of p52 associated genes were respectively identified, and a p-
value indicative of enrichment significance was calculated and further adjusted to the FDR using the 
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). Resultant GO terms were pruned to least 
common ancestors according to the Biological Process topology.  
From Human Protein Reference Database (v9) (Keshava Prasad et al., 2009), a connected protein 
interaction network was derived that comprised 9,218 nodes and 36,728 edges. p52 associated genes were 
mapped to this Human Protein Reference Database network, and then the Steiner tree algorithm (Klein 
and Ravi, 1995) was implemented to retrieve the most parsimonious subnetwork that joined together the 
terminal genes. 
 
Statistics 
Unpaired student t-tests were performed for comparisons between two groups. Values are 
presented as the mean ± SEM, and p<0.05 was considered statistically significant. Data were analyzed 
using GraphPad Prism 5.0 software (GraphPad Software, Inc.). 
 
Results 
 
p100/p52 expression is prevalent in human lung adenocarcinoma tumors 
To examine the distribution of p100/p52 expression in human lung adenocarcinoma tumors, we 
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performed p100/p52 immunostaining on a lung adenocarcinoma TMA (Figure 9A). After scoring each 
tumor sample on a 0 to 4 point scale based on the intensity and the localization of p100/p52 staining, we 
found p100/p52 expression in all lung adenocarcinomas tested (34/34) (Figure 9B). In addition, 47% 
(16/34) of tumors had mean scores >2, indicating some degree of nuclear staining for p52. In contrast, 
minimal p100/p52 expression was observed in normal lung parenchyma (Figure 9A). Together, these 
observations suggest that p100/p52 expression and p52 activation are frequent phenomena in lung 
adenocarcinoma tumors.  
 
Construction of transgenic mice with inducible expression of p52 in airway epithelium 
In order to investigate the role of p52 activation in lung cancer, we developed a novel mouse 
model of p52 expression in the airway epithelium using the tet-on system, placing a C-terminal FLAG-
tagged p52 under the control of a (tet-O)7-CMV promoter. Four founder lines were generated and mated 
to transgenic mice expressing rtTA under the control of the airway epithelial-specific CCSP promoter, 
generating mice designated CCSP-p52. 
To test the induction of p52 expression, CCSP-p52 mice were administered dox in drinking water 
(2 g/l) for one week. High levels of FLAG-p52 expression were detected in two lines of CCSP-p52 mice 
by western blotting of lung nuclear protein (Figure 10A), demonstrating successful induction of FLAG-
p52 expression and translocation of transgenic p52 into the nucleus. FLAG-p52 expression was also 
detectable in CCSP-p52 mice administered dox for one month (data not shown). No leaky FLAG-p52 
expression was detected in other organs after dox treatment or in the lungs in the absence of dox (data not 
shown). Long term dox treatment for 6 months resulted in sustained transgene expression (Figure 10B). 
FLAG immunostaining demonstrated FLAG-p52 expression in airway epithelium (Figure 10C). 
Together, these data show that CCSP-p52 mice administered dox express p52 in airway epithelium and 
that transgene expression results in nuclear p52 accumulation.  
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Figure 9:  p100/p52 expression is present in human lung adenocarcinomas.  
A) Representative images of p100/p52 immunostaining of lung adenocarcinoma and normal lung tissue (40x 
magnification). B) Distribution of p100/p52 immunostaining on a tumor tissue microarray (TMA) from 106 
human lung adenocarcinoma samples obtained from 34 patients. Tumor spots were scored as follows: 0 = no 
staining; 1 = diffuse cytoplasmic staining, no nuclear staining; 2 = dark granular cytoplasmic staining, no 
nuclear; 3 = nuclear staining in <25% of tumor cells; 4 = nuclear staining in >25% of tumor cells. Each tumor 
had at least two spots on the TMA, and the mean score was calculated for each tumor based on the individual 
score for each spot. 
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p52 over-expression in airway epithelium does not significantly alter inflammatory signaling 
We investigated whether p52 over-expression in vivo results in an inflammatory phenotype 
similar to canonical NF-κB pathway activation (Cheng et al., 2007). However, no significant difference in 
inflammatory cells was observed in lungs of CCSP-p52 mice compared to WT mice, and mice exhibited 
normal lung histology after dox treatment for 1 week, 1 month, or 6 months (Figure 10E, F). We also 
measured activation of other NF-κB family members by western blot using lung nuclear protein extracts 
from mice on dox for 1 week. As shown in Figure 10D, no difference was found in activation of other 
NF-κB family members. These data suggest that p52 over-expression in epithelial cells alone does not 
alter inflammatory signaling or inflammatory cell recruitment. 
 
CCSP-p52 mice develop an increased tumor burden and more advanced lesions after urethane 
injection 
In order to investigate the effect of p52 expression during lung tumorigenesis, we induced tumors 
in CCSP-p52 mice using the lung carcinogen urethane (ethyl carbamate), which causes tumors primarily 
through KRAS mutations (You et al., 1989) and, in FVB background mice, induces a mild inflammatory 
response (Stathopoulos et al., 2007). We first examined the effects of p52 over-expression on urethane-
induced inflammation and AAH lesion formation. For these short-term experiments, CCSP-p52 and WT 
mice on dox for one week received a single IP injection of urethane (1 g/kg) and remained on dox until 
euthanized. Total inflammatory cell numbers in BAL were counted at 10 days, 21 days (3 weeks), and 42 
days (6 weeks) after urethane injection. No differences were observed between CCSP-p52 and WT mice 
at any time point (Figure 11A). In addition, no differences in AAH lesion numbers were detected at 6 
weeks post-urethane (Figure 11B).  
To look at the later stages of tumor formation, CCSP-p52 and WT mice on dox for one week 
received a weekly IP urethane injection for 4 weeks and remained on dox until sacrifice 6 months after 
the first urethane injection. Lung tumor dimensions were measured, and lung tumors enumerated on lung 
sections, revealing a significant increase in tumor number and tumor size in CCSP-p52 lungs compared to  
Figure 10:  Characterization of a novel transgenic mouse model of lung epithelial 
p52 expression.  
Western blot demonstrating FLAG
CCSP-p52 mice on dox for A) 1 week
and CCSP-p52 mice on dox for 1 week (20x magn
using lung nuclear protein from mice on dox for 1 week. 
protein. E) Total BAL inflammatory cell numbers and F) representative 
lung sections (40x magnification) from WT and CCSP
week n=10-13/group, for 6 month n = 8/group
52 
 
-tagged p52 transgene expression in lung nuclear protein from WT and 
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photomicrographs of H&E
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Figure 11:  p52 expression does not affect urethane-induced inflammatory cell 
recruitment or formation of AAH lesions.  
A) Total inflammatory cells in BALs from WT and CCSP-p52 mice 10 days, 21 days (3 weeks), and 42 days 
(6 weeks) after urethane injection (10 and 21 day n=7-8 mice/group; 42 day n=22-24 mice/group). B) 
Average number of AAH lesions counted on lung sections from WT and CCSP-p52 mice 6 weeks after 
urethane (n=13-16 mice/group). 
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WT (Figure 12A, B). We further analyzed these tumors by histology, classifying tumors as adenomas, 
MIAs, or adenocarcinomas. Compared to WT mice, CCSP-p52 mice had an increased proportion of more 
advanced lesions (MIAs and adenocarcinomas, p<0.05) (Figure 12C, D). Taken together, these studies 
demonstrate that p52 expression does play an important role in lung tumor formation and contributes 
directly to increased tumor burden and enhanced tumor progression.  
 
p52 expression enhances proliferation through regulation of cell cycle genes 
To understand the mechanism by which p52 expression augments tumorigenesis, we performed 
microarray gene expression analysis using mRNA isolated from lungs of CCSP-p52 and WT mice on dox 
for 1 week. Genes were ranked based on the log fold change (logFC) of expression between WT and 
CCSP-p52 mice using a cut off of 0.41 (approximately 30% increase in gene expression in CCSP-p52 
mouse lungs) (Figure 13A). To evaluate the potential relevance of p52-regulated genes in human lung 
tumors, we focused only on genes that had known human homologs and were present in The Cancer 
Genome Atlas (TCGA) expression data from lung adenocarcinoma patients. Using these criteria, a total of 
71 genes associated with increased p52 expression were identified (Figure 13A, B; Table 1). Quantitative 
PCR was performed to validate increased expression of selected genes from the 71 gene list in CCSP-p52 
lungs (Figure 13C-E). To elucidate gene functions, we identified biological processes that were enriched 
in the p52-associated gene set using a Gene Ontology (GO) analysis. Applying a false discovery rate 
(FDR) of 0.001, we found that p52-associated genes were over-represented in processes related to cell 
cycle progression (Table 2), suggesting that p52 regulates expression of genes involved in proliferation. 
To validate this finding, we generated lung epithelial cells with stable p52 over-expression using 
the RLE-6TN rat lung epithelial cell line (designated RLE-p52). p52 over-expression and nuclear 
localization in these cells was confirmed by western blotting of nuclear protein (Figure 14A). We found 
that BrdU incorporation was enhanced in RLE-p52 cells compared to empty vector (RLE-EV) cells 
(Figure 14B), indicating that p52 stimulates proliferation of lung epithelial cells, thus supporting our 
microarray findings. 
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Figure 12:  p52 over-expression results in increased tumor number, size, and 
progression.  
A) Average tumor number per lung section and B) average tumor area from WT and CCSP-p52 mice 6 
months after urethane injection (3 sections/mouse; n=13-14 mice/group;*p<0.05 compared to WT mice.). C) 
Number and D) proportion of lung tumors classified as adenomas, minimally invasive adenocarcinomas 
(MIA), or adenocarcinomas (n=13-14 mice/group; *p<0.05 comparing total number of advanced lesions 
[MIAs and adenocarcinomas] between CCSP-p52 and WT mice). 
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Figure 13:  Identification of p52-regulated genes by microarray analysis.  
A) Schematic of process used to identify p52-regulated genes from microarray data generated from pooled 
mRNA samples from lungs of WT and CCSP-p52 mice on dox for 1 week (n=4/group). B) Volcano plot of 
log fold changes and differential expression p-values comparing CCSP-p52 mice to WT. Black dots represent 
all genes in the expression data matrix. Red dots represent 71 genes identified for further analysis. C-E) 
Expression microarray data validation by quantitative PCR of identified p52-regulated genes Ccna2 (C), 
Top2a (D), and Ube2c (E) measured in whole lung RNA from WT and CCSP-p52 mice on dox for 1 week 
(n=6 mice/group; *p<0.05 compared to WT). 
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Table 1:  Log fold change and p-value of 71 p52-regulated genes in CCSP-p52 mice 
versus WT and log fold change and q-value in human paired lung adenocarcinoma 
versus normal samples.  
 
Gene CCSP-p52 vs. WT tumor vs. normal 
(Human Homolog)  logFC  p-value logFC  q-value 
KIF20A 0.605 0.027 3.810 2.43E-18 
EXO1 0.502 0.012 3.977 2.80E-18 
UBE2C 0.912 0.001 3.995 2.89E-18 
NUF2 0.730 0.017 4.153 9.18E-18 
TOP2A 0.874 0.007 4.097 9.57E-18 
IQGAP3 0.634 0.005 3.987 9.97E-18 
KIF2C 0.577 0.044 4.027 2.80E-17 
CEP55 0.652 0.025 3.444 7.76E-17 
CDC20 0.574 0.014 4.057 9.43E-17 
RRM2 0.572 0.041 3.409 1.30E-16 
UHRF1 0.528 0.029 3.807 1.45E-16 
HELLS 0.731 0.010 3.062 2.08E-16 
SPAG5 0.621 0.040 3.267 2.85E-16 
CDCA8 0.594 0.017 3.257 3.37E-16 
CENPF 0.570 0.015 3.605 9.01E-16 
KIF11 0.767 0.017 2.878 2.17E-15 
CKAP2L 0.576 0.048 3.414 2.71E-15 
ASPM 0.456 0.020 3.867 3.81E-15 
ECT2 1.125 0.002 2.158 4.92E-15 
ESCO2 0.647 0.037 2.914 6.14E-15 
PBK 0.729 0.002 3.765 9.37E-15 
AURKB 0.574 0.026 3.625 2.29E-14 
CCNA2 0.860 0.010 3.049 2.37E-14 
KIF18B 0.611 0.024 3.795 3.33E-14 
CDCA2 0.517 0.045 3.213 8.41E-14 
RAD51 0.560 0.010 2.374 7.14E-13 
MCM6 0.577 0.006 1.623 4.45E-12 
GEMIN6 0.443 0.005 1.032 7.74E-12 
MCM2 0.469 0.022 2.027 2.04E-11 
CCNE2 0.685 0.019 2.299 2.97E-11 
SGOL2 0.480 0.046 1.676 1.04E-09 
DTL 0.723 0.006 2.348 2.99E-08 
PTGDS 0.627 0.001 -1.997 3.47E-08 
RACGAP1 0.535 0.029 1.527 6.13E-08 
MAL 0.564 0.003 -1.657 2.08E-05 
BRCA1 0.447 0.028 1.248 4.48E-05 
CFTR 0.914 0.006 -2.648 8.57E-05 
KLF10 0.469 0.040 -0.864 1.31E-04 
PSRC1 0.460 0.030 1.290 4.91E-04 
HSPA1B 0.997 0.022 0.663 1.59E-03 
ANGPTL4 0.660 0.009 1.466 0.012 
POLE 0.542 0.021 0.808 0.028 
GPX2 0.890 0.027 2.644 0.464 
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HSPA1A 0.997 0.022 0.473 1.00 
MOXD1 0.418 0.047 0.671 1.00 
CCDC18 0.411 0.016 0.712 1.00 
CRYGN 0.421 0.037 282.976 1.00 
MAGEB1 0.425 0.023 193.612 1.00 
LCN2 0.585 0.036 1.387 1.00 
HSPH1 0.689 0.033 0.379 1.00 
PAPPA2 0.608 0.007 -176.187 1.00 
CTNND2 0.547 0.035 -126.328 1.00 
CDKN1A 0.432 0.025 -0.415 1.00 
CYP2C8 0.417 0.022 -106.253 1.00 
MAT1A 0.409 0.031 0.815 1.00 
NFKB2 0.720 0.022 0.279 1.00 
GRIN2A 0.416 0.012 -70.563 1.00 
HIST1H2AA 0.545 0.016 52.794 1.00 
TNIP3 2.112 0.003 -0.598 1.00 
AREG 0.565 0.012 -0.599 1.00 
DIAPH3 0.441 0.025 0.303 1.00 
ADAMTS9 0.564 0.040 -0.261 1.00 
YBX2 0.556 0.001 91.762 1.00 
ATF7IP2 0.443 0.025 0.167 1.00 
SLC26A4 1.295 0.020 0.262 1.00 
GIF 0.485 0.003 35.537 1.00 
EPHA7 0.573 0.035 -17.780 1.00 
TNFSF9 0.796 0.047 0.093 1.00 
ELOVL7 0.455 0.017 -0.075 1.00 
RNASE2 0.742 0.031 1.143 1.00 
OR4K1 0.471 0.009 0.070 1.00 
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Table 2:  GO analysis of p52 regulated genes (FDR=0.001).  
 
Gene Ontology term  
(Biological Process) 
Reference 
set size 
Expected 
Count 
Observed 
count 
Adjusted  
p-value
a 
 
Cell cycle checkpoint 230 0.98 9 2.59E-05 
Mitotic cell cycle phase transition 443 1.88 11 8.83E-05 
DNA unwinding involved in DNA 
replication 8 0.03 3 1.39E-04 
Regulation of cell division 221 0.94 8 1.39E-04 
Regulation of attachment of spindle 
microtubules to kinetochore  9 0.04 3 1.81E-04 
DNA replication initiation 29 0.12 4 1.88E-04 
Regulation of cell cycle process 435 1.85 10 3.68E-04 
Chromosome organization 765 3.25 13 4.04E-04 
Spindle assembly involved in mitosis 15 0.06 3 7.44E-04 
ap-values have been adjusted using the Benjamini-Hochberg method.  
 
  
 Figure 14:  p52 promotes proliferation 
A) Western blot for p52 and FLAG using nuclear lysates from RLE
expression vector (RLE-p52) or control empty vector (RLE
Quantification of BrdU incorporation 
(**p<0.01 compared to RLE-EV).
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in vitro.  
-6TN cells stably transfected with a p52 
-EV). TBP was used as a loading control.
of RLE-p52 and RLE-WT cells, normalized to total viable cells 
 
 
 
 B) 
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Expression of p52-regulated genes predicts prognosis of lung cancer patients 
To investigate the relevance of p52 expression in human lung cancer, we examined the 
expression of the 71 identified p52-regulated genes in matched tumor and normal samples. A differential 
expression test using a paired t-test was performed for each gene in paired tumor and normal samples 
from 54 lung adenocarcinoma patients available in the TCGA database. Up-regulated genes were defined 
as having both a logFC>1 and FDR<0.01. From the set of 20,501 genes, 1,274 up-regulated genes (6.2%) 
were identified in tumors compared to matched normal samples (Table 3). Of the 71 p52-regulated genes, 
35 were up-regulated in tumors (49.3%), indicating a significant over-representation of p52-regulated 
genes in tumor samples compared to normal (hypergeometric test p=6.0x10-25) (Table 1, Table 3, Figure 
15) and suggesting that p52 is important in human lung tumors. 
Since we observed more advanced tumors in urethane-treated CCSP-p52 mice, we wondered 
whether increased p52 expression would correlate with a worse prognosis in lung cancer patients. 
Therefore, we investigated the relationship between increased expression of p52-associated genes and 
patient outcomes using tumor expression data and clinical information from the TCGA dataset. 437 
primary lung adenocarcinoma samples were divided into two equal groups based on the collective 
expression level of the 71 p52-associated genes by summing expression from all 71 genes (Table 4). 
Kaplan-Meier survival analysis revealed that patients with high expression of p52-associated genes had a 
significantly worse prognosis (log-rank test p=0.004) (Figure 16A). To validate this analysis, we divided 
patients by a second method into two equal groups. For the second method, sample division was based on 
summed “votes” from the 71 genes, where one gene counted as a vote for one sample if its expression in 
the sample was higher than the median expression level for this gene across samples (thus preventing a 
tumor sample with only a few highly-expressed genes from being placed in the “high expression group”). 
Using this method, Kaplan-Meier survival analysis again revealed that patients with high expression of 
p52-associated genes had significantly worse outcomes (log-rank test p=0.021) (Figure 16B). 
Furthermore, survival analysis of only Stage I patients revealed that patients with high expression of p52-
associated genes still had a significantly worse prognosis (log-rank test p=0.036) (Figure 16C). Together,  
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Table 3:  Over-representation of p52-associated genes in up-regulated genes 
identified in human lung adenocarcinomas tumor samples compared to matched 
normal controls.  
 
 
All genes  
Significantly up-regulated 
genes
a 
 
p-value of over-
representation 
All genes (from TCGA) 20,501 1,274 6.0E-25 
p52 genes 71 35 
aUp-regulated genes defined as logFC > 1 and FDR <0.01.  
 
  
 Figure 15:  p52-associated 
tumor samples.  
Volcano plot of log fold changes and 
dots represent all genes in the expre
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genes are up-regulated in human lung adenocarcinoma 
differential expression p-values of tumor versus normal samples. 
ssion data matrix. Red dots represent p52-associated genes. 
 
Black 
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Table 4:  Division of Stage I-IV lung adenocarcinoma patients based on summed 
expression of p52-associated genes.  
 
 
N  High expression group  
Low expression 
group 
Stage 1 patients  235  100 135 
Stage 2 patients  103  63 40 
Stage 3 patients  75  40 35 
Stage 4 patients  23  14 9 
Total  437  218
a 
 
219  
aOne sample in the high expression group had data for survival and expression but no stage information. This 
sample was included in overall analysis but not in stage-specific analysis.  
 
  
 Figure 16:  Expression of p52
cancer patients.  
Kaplan-Meier survival curves of overall patient survival data based on 
expression “votes”of p52-associated
for expression “votes”). C) Kaplan
expression of p52-associated genes in tumors (log
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-associated genes correlates with prognosis of lung 
(A) summed expression or (B) on 
 genes in tumors (log-rank test, p=0.004 for summed expression
-Meier survival curve of Stage I patient survival data based on summed 
-rank test p=0.036). 
 
; p=0.021 
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these data suggest that expression of p52-associated genes in tumors of lung cancer patients leads to 
shorter survival and can be used to predict patient outcome in early stage lung cancer patients.  
Since the GO analysis suggested that p52 regulates a number of genes that have highly related 
functions, we extracted a protein subnetwork connecting the p52-associated genes from a human protein-
protein interaction network. The 35 p52-associated genes identified in tumor versus normal samples were 
used to generate a network consisting of genes from the p52-associated gene list as well as 13 imputed 
mediator genes (Figure 17A). To test the strength of this protein interaction network, a survival analysis 
was performed based only on expression of the 13 imputed mediator genes. High expression of the 
imputed genes also correlated with shorter survival (log-rank test p=0.047 by expression summation, 
p=0.097 by votes) (Figure 17B, C), supporting the strength of this p52-derived interaction network in 
predicting patient prognosis. 
 
Discussion 
These studies provide the first evidence of the involvement of p52 in lung cancer, identifying p52 
as a novel mediator of lung cancer progression through regulation of cell cycle genes. For these studies, 
we generated a novel transgenic mouse model that enables expression of the NF-κB family member p52 
in specific cell populations and characterized this model in airway epithelial cells. In CCSP-p52 mice, 
p52 over-expression did not induce activation of other NF-κB family members or inflammatory cell 
recruitment, even after injection with the lung carcinogen urethane. Still, p52 over-expression in the 
airway epithelium led to more tumors, larger tumors, and more advanced tumors after urethane injection. 
In vitro studies and gene expression microarray analysis revealed that p52 expression promotes 
proliferation of lung epithelial cells by increasing expression of a number of cell cycle-associated genes. 
Expression of these p52-associated genes was significantly associated with lung tumors compared to 
normal lung tissue in lung cancer patients. In addition, increased expression of p52-associated genes in 
lung tumors correlated with a significantly shorter survival, even for Stage I patients. Finally, we 
generated a protein-protein interaction network using the p52-associated genes found in tumors and 
Figure 17:  Expression of genes in p52
poor prognosis of lung cancer patients. 
A) Protein-protein interaction network generated using 35 p52
Table 1 and Table 3). Pink circles a
and blue circles are imputed genes
summed expression or (C) expression “votes” of imputed mediator genes (log
expression; p=0.097 for expression “votes”
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-derived protein interaction correlate with 
 
-associated genes associated with tumors (
re genes identified as p52-regulated genes through microarray analysis,
. Kaplan-Meier survival curves of overall patient survival based on 
-rank test, p=0.047 
). 
 
see 
 
(B) 
for summed 
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examined patient survival based on expression of the imputed mediator genes, revealing poor prognosis 
with high expression of the imputed genes and demonstrating the strength of this p52-derived gene 
network in predicting patient prognosis. Taken together, these data suggest that p52 is an important 
contributor to lung tumorigenesis and that modulation of p52 activity or its downstream targets could 
potentially improve patient outcome.  
Nuclear localization of p52 has been observed in a number of different tumor types, but the 
understanding of the function of p52 activation in vivo during carcinogenesis has remained limited due to 
the constraints of available models. In other studies using a mouse model with global truncation of 
theNfkb2 gene deleting the C-terminal inhibitory domain of p100, mice die from gastric hyperplasia 
(Ishikawa et al., 1997). However, unlike our studies, the individual contribution of inflammatory cells and 
surrounding stroma with dysregulated p52 activation was not separated from the effects of p52 activation 
in the epithelial cells of the stomach. Using a transgenic model with expression of the full Nfkb2 gene 
under the control of the β-lactoglobulin milk protein promoter, Connelly et al. demonstrated ductal 
thickening and hyperplasia in the mammary gland after three pregnancies (Connelly et al., 2007), but in 
this model, expression was limited to the periods of milk production during the late stages of pregnancy 
and lactation. Studies described here improve upon these models by using an inducible p52-expressing 
mouse. The advantages of a mouse model with inducible p52 expression are many and include: p52 can 
be expressed with any cell type-specific promoter coupled to a reverse tetracycline transactivator, the 
duration of p52 expression can be manipulated, and p52 expression can be combined with other inducible 
mouse models, including oncogenic tumor models. Future studies using this p52-inducible model to 
modulate the duration of expression in the urethane model and to express p52 in other cell types and in 
combination with other inducible models will be valuable for developing a broader understanding of p52 
activation in lung cancer and other contexts.  
Like CCSP-p52 mice, activation of canonical NF-κB signaling in transgenic mice expressing 
constitutively active IKKβ in airway epithelium increases tumor burden following urethane treatment 
(Zaynagetdinov et al., 2011b). However, in contrast to non-canonical pathway activation, canonical NF-
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κB activation causes a profound immune/inflammatory response, which promotes lung carcinogenesis 
through paracrine signaling (Cheng et al., 2007; Zaynagetdinov et al., 2011b). In the setting of lung 
epithelial canonical NF-κB activation, T-regulatory cell recruitment creates an immunosuppressive 
microenvironment that supports increased tumor formation (Zaynagetdinov et al., 2011b). In the context 
of non-canonical pathway activation, our studies indicate that non-canonical NF-κB signaling primarily 
regulates genes that function in a cell autonomous manner to promote carcinogenesis. 
Among the NF-κB family members, p52 is structurally most similar to p50. Both undergo 
proteasomal processing of larger precursors to generate the active form, which can enter the nucleus to 
regulate gene transcription, and both have a Rel-homology domain enabling dimerization and DNA 
binding but lack a transactivation domain. Kravtsova-Ivantsiv et al. recently demonstrated that p50 over-
expression suppressed in vitro colony formation of cancer cell lines as well as xenograft tumor growth 
(Kravtsova-Ivantsiv et al., 2015). In contrast, we observed increased proliferation of lung epithelial cells 
in vitro and increased tumor size and number in vivo as a result of p52 expression. In other contexts, p52 
activation has also been shown to promote proliferation. Nadiminty et al. observed that p52 over-
expression enhanced proliferation of prostate cancer cells in androgen-deprived conditions by stimulating 
cyclin D1 expression (Nadiminty et al., 2008). Similarly, increased p100 expression in mammary glands 
led to hyperplasia and increased cyclin D1 (Connelly et al., 2007). Although we did not identify cyclin D1 
as an upregulated gene in our microarray analysis, both cyclin E2 and cyclin A2 were increased in CCSP-
p52 lungs (Table 1). Despite the structural similarity between p50 and p52, these studies suggest that they 
function differently during tumorigenesis, which may be due to the differential affinities of each for 
specific promoter sequences or their propensity to interact with other NF-κB family members and 
transcriptional binding partners (Siggers et al., 2011; Zhao et al., 2014). 
Although p100/p52 expression appears to be common in lung adenocarcinomas, how this 
pathway becomes activated remains unclear. Proteolytic processing of p100 to p52 can be activated by a 
number of stimuli, including lymphotoxin β (Dejardin et al., 2002), CD40 ligand (Coope et al., 2002), 
ROS (Iannetti et al., 2014), and STAT3 signaling (Nadiminty et al., 2006), suggesting that p52 activation 
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can occur in a tumor as a result of oncogenic signaling or microenvironmental stimuli. Additional 
evidence indicates that crosstalk occurs between the canonical and non-canonical NF-κB pathways, 
suggesting that factors leading to canonical pathway activation could also activate p52 (Liptay et al., 
1994). Further investigations are necessary to identify the mechanisms behind p52 activation in tumors as 
well as the individual functional contributions of canonical and non-canonical NF-κB signaling during 
lung tumorigenesis.  
In these studies, we took a gene list derived from p52 expression in a mouse model and 
demonstrated that these genes predict survival of early stage lung cancer patients. Since p52 was only 
over-expressed in a subset of cells in lungs of CCSP-p52 mice, the signal in our gene expression 
microarray analysis was likely diluted, explaining why we did not observe large expression differences 
between CCSP-p52 and WT lungs. However, we were still able to identify genes with significant 
expression changes as a result of p52 expression and these genes were highly related in function, 
indicating that p52 regulates expression of a network of related genes. Ianetti et al. also identified 
significant changes in many cell cycle-associated genes from microarray analysis of Nfkb2 knockdown 
fibroblasts, and several of these genes overlap with our gene set (Iannetti et al., 2014). Because many of 
the genes in the gene list are known cell cycle regulators that have well-established roles in 
carcinogenesis, p52 modulation may be an attractive therapeutic target for drug development. In addition, 
inhibitors for several of the nodes in our p52-derived protein interaction network are being developed for 
clinical use, including aurora kinase B, CDK1, and polo-like kinase 1, suggesting that treatment with 
these drugs alone or in combination may be beneficial in patients with p52 activation in their tumors. 
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CHAPTER IV 
 
P52 OVER-EXPRESSION INCREASES EPITHELIAL APOPTOSIS, ENHANCES LUNG 
INJURY, AND REDUCES SURVIVAL AFTER LPS TREATMENT 
 
Parts of this chapter were originally published in The Journal of Immunology. Saxon JA, Cheng D-S, Han W, 
Polosukhin V, McLoed AG, Richmond BW, Gleaves LA, Tanjore H, Sherrill TP, Barham W, Yull FE, 
Blackwell TS. 2016. p52 over-expression increases epithelial apoptosis, enhances lung injury, and reduces 
survival after LPS treatment. J. Immunol. 196(4) 1891-1899. Copyright © 2016 The American Association of 
Immunologists, Inc. 
 
Rationale 
NF-κB regulates a number of key genes involved in cellular processes such as proliferation, 
apoptosis, and inflammation. The NF-κB transcription factor family contains 5 members (p65/RelA, 
p100/p52, p105/p50, RelB, and c-Rel). Traditionally, NF-κB signaling is associated with activation 
through either the canonical or non-canonical signaling pathways. In the non-canonical pathway, a 
heterodimer consisting of p100 and most commonly RelB remains sequestered in the cytoplasm due to 
the IκB-like inhibitory C-terminus of p100. Upon activation, p100 is phosphorylated and undergoes 
partial proteolytic processing to p52, enabling the p52-containing heterodimer to translocate into the 
nucleus. While many studies have identified crucial roles for canonical NF-κB signaling in inflammatory 
diseases, metabolic disorders, and cancer, few have investigated the involvement of non-canonical NF-κB 
signaling in these contexts. Global knockout of either Relb or Nfkb2 (the genes for RelB and p100/p52) 
causes defects in secondary lymphoid organ development and impaired immune responses (Caamaño et 
al., 1998; Franzoso et al., 1998; Weih et al., 1995). Therefore, non-canonical NF-κB signaling has 
primarily been studied in hematopoietic cells, where it is an important pathway for regulating chemokine 
genes required for normal lymphoid organ development (Dejardin et al., 2002; Weih et al., 2001). 
However, little is known about the function of non-canonical NF-κB signaling in non-immune cell types. 
Acute respiratory distress syndrome (ARDS) is a life-threatening form of hypoxemic respiratory 
failure that results in substantial morbidity and mortality. ARDS is characterized by an influx of 
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inflammatory cells, epithelial apoptosis, and vascular permeability. IT treatment of mice with Escherichia 
coli LPS is commonly used as a model of ARDS. We have previously shown that NF-κB signaling in the 
lung epithelium regulates the inflammatory response after LPS stimulation (Cheng et al., 2007), 
suggesting that epithelial NF-κB signaling is a critical component of ARDS pathogenesis. Although the 
role of the non-canonical NF-κB pathway in LPS-induced inflammation is unknown, studies with lung 
epithelial cells in vitro have shown that LPS stimulation induces non-canonical NF-κB activation with 
slower and more protracted kinetics compared to canonical NF-κB activation and that non-canonical NF-
κB signaling may be important for regulation of pro-inflammatory cytokines (Tully et al., 2012).  
We observed increased nuclear accumulation of the non-canonical NF-κB signaling component 
p52 in the airways of ARDS patients. To investigate the effect of p52 activation in vivo during acute 
inflammation, we used a transgenic mouse model with inducible expression of p52 specifically in airway 
epithelial cells. We found that p52 over-expression in conjunction with LPS stimulation led to increased 
mortality and exaggerated lung injury, along with increased epithelial cell apoptosis. Together, these 
studies demonstrate a novel role for non-canonical NF-κB signaling in cell survival/apoptosis during 
cellular stress and implicate p52 as a factor affecting the severity of ARDS pathogenesis. 
 
Materials and Methods 
 
Animal model 
CCSP-tTS/(tet-O)7-FLAG-p52 mice on an FVB background were mated to CCSP-rtTA 
homozygous mice (gift from Dr. J.A. Whitsett, University of Cincinnati, Cincinnati, OH) to generate 
CCSP-p52 mice, which inducibly express FLAG-tagged p52 in the airway epithelium as described in 
Chapter 3. CCSP-p52 mice generated from two separate CCSP-tTS/(tet-O)7-FLAG-p52 founder lines 
were used for these studies. Age- and sex-matched transgenic mice along with genotype-negative 
littermate controls (called WT in our studies) were used in experiments. Transgene expression was 
activated by administering 2 g/l dox along with 2% sucrose in drinking water. Water was replaced twice 
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weekly. Mice were sacrificed at indicated time points, and lungs were lavaged as previously described 
(Zaynagetdinov et al., 2011b). The left lung was tied off and flash-frozen in liquid nitrogen, and the right 
lung was perfused and fixed by inflating with 10% neutral-buffered formalin. Total and differential BAL 
cell counts were determined as previously described (Stathopoulos et al., 2007). All animal care and 
experimental procedures were approved and conducted according to the guidelines of the Vanderbilt 
University Institutional Animal Care and Use Committee. 
 
LPS, bleomycin, and RelB adenovirus administration 
To establish transgene expression, mice were placed on dox for 1 week prior to IT LPS, 
bleomycin, or RelB adenovirus administration, and they remained on dox until sacrifice. For IT 
treatments, mice were anesthetized with isofluorane. Escherichia coli LPS (serotype 055:B5; Sigma-
Aldrich) was diluted in sterile PBS and delivered IT at a dose of 3 µg/g body weight. Bleomycin (0.08 
units) diluted in sterile saline was administered IT. 5 x 108 pfu of RelB-His adenovirus containing murine 
RelB with a His tag (Ad-RelB; ABM) or control luciferase adenovirus (Ad-Luc; gift from Dr. A. Powers, 
Vanderbilt University, Nashville, TN) was delivered IT. Inflammatory cell recruitment was assessed 96 
hours after adenoviral administration. For experiments with LPS stimulation after adenovirus 
administration, LPS was given IT 96 hours after adenoviral delivery.  
 
Lung histology 
H&E staining was performed on 5 µm lung sections to assess lung histology. A pathologist 
scored lung fibrosis on H&E-stained sections as previously described using a 0 to 4 point scale (0 = 
normal lung architecture; 1 = increased thickness of ≤50% of interalveolar septa; 2 = thickening of >50% 
of interalveolar septa without fibrotic foci formation; 3 = thickening of the interalveolar septa with 
isolated fibrotic foci formation; 4 = formation of multiple fibrotic foci with distortion of parenchymal 
architecture) (Lawson et al., 2005).  
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Immunostaining 
For TUNEL immunofluorescence staining, lung sections were stained using the fluorescein In 
Situ Cell Death Detection Kit (Roche), and TUNEL positive cells were counted in fifteen 60x fields using 
fluorescent confocal microscopy. Mean scores were calculated for each animal. For TUNEL co-
immunofluorescence staining with CCSP or SPC, lung sections were first stained with anti-CCSP (S-20; 
Santa Cruz) or anti-SPC antibody (Millipore) followed by the TUNEL staining protocol. Using 
fluorescent confocal microscopy, SPC and TUNEL double-positive cells were enumerated in ten 20x 
fields, and total CCSP and TUNEL double-positive cells were counted on each lung section. To assess 
nuclear p52 in human lungs, immunostaining using an anti-p52 antibody (C-5, Santa Cruz) was 
performed on normal lung sections from 4 life-long non-smokers and on lung sections from 4 patients 
with ARDS. ARDS lung sections were a generous contribution from Dr. Lorraine Ware (Vanderbilt 
University, Nashville, TN). All patients had no known chronic lung disease. 
 
Cell viability measurements 
Rat type II alveolar epithelial cell line RLE-6TN (ATCC) were maintained at 37ºC 5% CO2 in 
DMEM (Invitrogen) with 4.5 g/l glucose and 2mM L-glutamine, supplemented with 10% FBS, 100 
units/ml penicillin, and 100 µg/ml streptomycin. Generation and validation of stable p52 over-expressing 
(RLE-p52) and control empty vector (RLE-EV) cells is described in Chapter 3. Viability of parental cells 
(RLE-WT), RLE-EV, and RLE-p52 RLE-6TN cells was assessed using the CellTiter-Glo Luminescent 
Cell Viability assay (Promega) according to the manufacturer’s protocol. For serum starvation 
experiments, an equal number of RLE-WT, RLE-EV, and RLE-p52 cells were plated in 96 well plates in 
10% serum medium as described above. Eight hours later, when cells had adhered to the wells, cells were 
switched to medium lacking serum, and cell viability was assessed after 12, 18, and 24 hours in medium 
without serum. Percent survival was determined by normalizing no serum viability measurements to 
viability measurements in 10% serum medium for each cell line at each time point. For H2O2 treatment 
experiments, an equal number of RLE-EV and RLE-p52 cells were plated in 96 well plates. After 
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overnight incubation, cells were treated with 100 µM H2O2, and cell viability was assessed at 24 hours. 
Percent survival was determined by normalizing H2O2-treated viability measurements to viability 
measurements in control (untreated) cells. 
 
Western blot analysis  
Nuclear protein was prepared from lung tissue using the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific), separated by SDS-PAGE, transferred to nitrocellulose 
membranes, and probed using the following antibodies:  FLAG (F3165, Sigma), p100/p52 (4882, Cell 
Signaling), p65 (C-20, Santa Cruz), p50 (C-19, Santa Cruz), RelB (C-19, Santa Cruz), cRel (C, Santa 
Cruz), and TBP (N-12, Santa Cruz). Whole cell lysates were prepared from RLE-6TN cells using RIPA 
buffer (Invitrogen) and probed with antibodies for caspase-3 (9662, Cell Signaling) and β-actin (AC-74, 
Sigma). Immunodetection was performed using the corresponding AlexaFluor-conjugated antibodies and 
the Odyssey Infrared Imaging System (LI-COR Biosciences). All images were converted to grayscale. 
 
Quantitative real-time PCR 
Total mRNA was isolated using the RNeasy Mini kit (Qiagen) according to the manufacturer’s 
instructions. Quantitative real-time PCR was performed using Sybr Green PCR Master Mix (Applied 
Biosystems) and the following primer sets:  Cxcl12 (F: CCCATTCTCCTCATCCTCAT; R: 
ACTCTGCTCTGGTGGAAGGT) (Petty et al., 2007), Cxcl13 (F: AACTCCACCTCCAGGCAGAATG; 
R: TGTGTAATGGGCTTCCAGAATACC) (Hojgaard et al., 2006), Ccl19 (F: 
GGCCTGCCTCAGATTATCTGCCAT; R: GGAAGGCTTTCACGATGTTCC), Ccl21 (F: 
GGACCCAAGGCAGTGATGGAG; R: CTTCCTCAGGGTTTGCACATAG) (Proietto et al., 2008), 
RelB (F: GGGCATCCAGTGTGTTAGGAAGAA; R: GGAAGCAGATCCTGACGACATTCA), and 
GAPDH (F: TGAGGACCAGGTTGTCTCCT; R: CCCTGTTGCTGTAGCCGTAT). Expression values 
were normalized to GAPDH using the ∆CT method. 
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For the quantitative real-time PCR array analysis, RLE-WT, RLE-EV, and RLE-p52 cells plated 
in 10 cm plates underwent serum starvation for 18 hours as described for cell viability measurements. 
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol. RNA was converted to cDNA using the RT2 First Strand Synthesis Kit (Qiagen). Apoptosis 
genes were assessed using the Rat Apoptosis RT2 Profiler PCR array (Qiagen) according to the 
manufacturer’s instructions. Four biological replicates were run for each cell type, and threshold cycle 
values greater than 32 were discarded from the analysis. Expression values for each sample were 
normalized to the mean of 5 measured housekeeping genes using the ∆CT method. 
 
Multiplex Cytokine Bead Array 
Levels of IFNγ, IL-1β, MCP-1, G-CSF, IL-6, KC, and MIP-1α were measured in BAL fluid and 
lung lysates as part of a multiplex mouse cytokine magnetic bead array panel (EMD Millipore, 
Darmstadt, Germany) using a Luminex 100 analyzer. Assays were performed according to the 
manufacturer’s instructions with assistance from the VUMC Hormone Assay and Analytical Services 
Core. Other analytes in the panel that were below the limit of detection include GM-CSF, IL-4, IL-10, 
and IL-12p40. 
 
ELISAs 
Lung nuclear protein was isolated as described for western blot analysis, and p52 was detected 
using the TransAM NF-κB ELISA kit (Active Motif). Albumin was measured in cell-free BAL 
supernatants using the mouse albumin ELISA from GenWay Biotech, Inc. G-CSF, Mip-1α, KC, (R&D 
Systems) MCP-1, IL-1β, and IFNγ (Biolegend) were measured in whole lung lysates. All ELISAs were 
performed according to manufacturer’s instructions. 
 
Statistics 
 Data were analyzed using GraphPad Prism 5.0 software (GraphPad Software, Inc.), and all values 
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are presented as the mean ± SEM. Unpaired Student’s t-tests were performed for comparisons between 
two groups. To analyze differences among more than two groups, one-way ANOVA followed by a 
Tukey’s post-test was used. For the Kaplan-Meyer survival analysis, a log-rank test was employed. 
p≤0.05 was considered statistically significant. 
 
Results 
 
Increased nuclear p52 accumulation in lungs of ARDS patients 
To investigate whether non-canonical NF- κB signaling is activated in the lungs of ARDS 
patients, we performed p100/p52 immunostaining on lung sections from patients with ARDS and control 
subjects. Faint cytoplasmic staining but no nuclear staining was observed in airways from normal lungs 
(Figure 18A, B). In contrast, ARDS airways and parenchyma had a marked increase in nuclear as well as 
cytoplasmic staining (Figure 18A, B). This finding of increased nuclear p52 staining in airways and lung 
parenchyma of ARDS patients suggests that p52 activation could influence ARDS pathogenesis. 
 
CCSP-p52 mice exhibit exaggerated inflammation, lung injury, and mortality after IT LPS 
In contrast to canonical NF-κB signaling, which is increased in the lungs within the first 24 hours 
following IT injection of Escherichia coli LPS (Blackwell et al., 1999), we found that treatment of WT 
mice with IT LPS (3 µg/g body weight) leads to increased nuclear p52 in the lungs that peaks at 48 hours 
(Figure 19). To investigate the function of p52 in the context of LPS stimulation in vivo, IT LPS was 
administered to dox-treated CCSP-p52 and WT mice. A significant increase in mortality was observed in 
CCSP-p52 mice compared to WT mice beginning 72 hours after LPS (Figure 20A). We measured 
albumin in BAL fluid as a marker of lung injury and found that albumin levels were significantly higher 
in BAL from CCSP-p52 mice 48 hours after LPS administration (Figure 20B). Total inflammatory cell 
numbers in BAL were also increased in CCSP-p52 mice compared to WT mice at 48 hours after LPS 
assessed by western blotting of lung nuclear protein from mice 24, 48, and 72 hours after LPS to  
Figure 18: Increased nuclear p52 staining in airways of ARDS patients. 
Photomicrographs of p52 immunostaining of airways (A) and lung parenchyma (B) from normal and ARDS 
human lung sections (40x magnification). 
individuals per group. 
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Immunostaining is representative of lung sections from 4 
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Figure 19:  LPS stimulation leads to increased p52 activation in vivo.  
p52 binding measured by ELISA in lung nuclear protein from WT mice at the indicated time points after LPS 
(n=3/time point). 
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determine whether altered activation of other NF-κB family members was associated with the enhanced 
inflammatory influx in CCSP-p52 mice. Compared to WT lungs, no differences in activation of other NF-
κB family members in CCSP-p52 lungs were observed at any time point (Figure 20G, H and data not 
shown).  
Since we observed increased inflammatory cells in BAL from CCSP-p52 mice following LPS 
treatment, we expected to find increased levels of cytokines/chemokines in the lungs. Therefore, we 
measured a panel of mediators in BAL fluid at 24 hours after LPS treatment and in lung lysates at 24, 48, 
and 72 hours after LPS. Surprisingly, no differences were found in levels of G-CSF, IL-1β, MCP-1, MIP-
1α, IFNγ, IL-6, or KC at any time point (Figure 21A-D). We also measured expression of previously 
described non-canonical NF-κB signaling targets Cxcl12, Cxcl13, Ccl19, and Ccl21 (Dejardin et al., 
2002) in lung lysates from CCSP-p52 and WT mice and found no differences between groups (Figure 
21E). To determine whether inflammatory cells from CCSP-p52 mice produced more inflammatory 
cytokines, we isolated macrophage and neutrophil populations from the lungs of WT and CCSP-p52 mice 
48 hours after LPS and measured expression of KC, TNF-α, IL-6, and IL-1β by quantitative real-time 
PCR. However, no increases in cytokine production by inflammatory cells from CCSP-p52 mice were 
observed (data not shown). Together, these data show that over-expression of p52 in the airway 
epithelium does not increase cytokine expression in this model. 
The p52 precursor p100 preferentially binds to RelB in the cytoplasm, inhibiting its nuclear 
translocation (17). When non-canonical signaling is activated, processing of p100 to p52 induces 
translocation of RelB/p52 heterodimers into the nucleus (17, 18). To investigate the effect of RelB over-
expression in combination with p52 over-expression on inflammatory cell recruitment, dox-treated WT 
and CCSP-p52 mice were administered adenoviral RelB (Ad-RelB) or control adenovirus (Ad-Luc) by IT 
injection. RelB over-expression in the lungs was confirmed by quantitative real-time PCR (Figure 22A), 
and inflammatory cell recruitment was assessed 96 hours after adenoviral administration. RelB over-
expression caused a significant increase in inflammatory cell recruitment, characterized by increased 
macrophages, lymphocytes, and neutrophils in both WT and CCSP-p52 mice compared to mice treated  
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Figure 20:  Treatment of CCSP-p52 mice with LPS results in increased 
inflammation, lung injury, and mortality.  
A) Kaplan-Meier survival curve of WT and CCSP-p52 mice after LPS stimulation (n=57-60/group; log-rank 
test p<0.01). B) Albumin measured by ELISA in lavage fluid from WT and CCSP-p52 mice at baseline and 
after LPS stimulation (for baseline n=4/group, for 24 and 72 hour n=7-8/group, for 48 hour n=12-
17/group;*p<0.05 compared to WT). C) Total BAL inflammatory cell numbers at baseline and after LPS 
stimulation (n=10-27/group, **p<0.01 compared to WT). BAL inflammatory cell differentials for CCSP-p52 
and WT mice 48 hours (D) and 72 hours (E) after LPS (n=12-26/group; **p<0.01 compared to WT). F) 
Representative photomicrographs (40x magnification) from lungs of WT and CCSP-p52 mice at 48 hours 
after LPS. G) Western blot and H) densitometry for NF-κB family members using lung nuclear protein from 
mice at 48 hours after LPS stimulation. TBP was used as a loading control. H) (***p<0.001 compared to 
WT). 
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Figure 21:  p52 over-expression does not affect chemokine production after LPS 
stimulation.  
Levels of  inflammatory mediators in (A) BAL fluid at 24 hours after LPS treatment and in lung lysates at (B) 
24 hours, (C) 48 hours, and (D) 72 hours after LPS treatment in WT and CCSP-p52 mice (n=3-10 
mice/group). E) Quantitative real-time PCR analysis of Cxcl12, Cxcl13, Ccl19, and Ccl21 expression in 
lungs of WT and CCSP-p52 mice 24 hours after LPS stimulation (n=4-5 mice/group). 
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with Ad-Luc (Figure 22B-E). However, in the context of LPS stimulation, RelB over-expression did not 
affect inflammatory cell influx into the lungs of CCSP-p52 mice after LPS treatment (Figure 22D, E). 
Together, these data indicate that RelB over-expression causes an inflammatory response independent of 
p52. However, RelB over-expression did not augment the effects of p52 over-expression in the context of 
LPS stimulation, indicating that p52 is the most important component of the non-canonical NF-κB 
signaling pathway responsible for altering the response to LPS. 
To determine whether CCSP-p52 mice are more susceptible to lung injury, we tested their 
response to a different insult by administering IT bleomycin (0.08 units), a chemotherapeutic agent that 
causes lung inflammation, injury, and fibrosis in mice. Three weeks after bleomycin administration, no 
differences in BAL inflammatory cells or lung fibrosis were observed between dox-treated WT and 
CCSP-p52 mice (Figure 23), suggesting that p52-mediated exacerbation of lung injury may be dependent 
on the stimulus. 
 
p52 over-expression causes apoptosis of airway epithelial cells after LPS 
Since no differences in cytokine expression were observed between LPS-treated WT and CCSP-
p52 mice, we wondered whether p52 over-expression could contribute to lung injury by altering epithelial 
cell survival. Therefore, we measured apoptosis by TUNEL staining in WT and CCSP-p52 lung sections 
at 24 and 48 hours after LPS. While no significant differences in apoptosis were observed at 24 hours 
after LPS, a trend toward increased apoptosis in CCSP-p52 lungs was present at 48 hours after LPS 
(Figure 24A). By co-immunofluorescence staining of TUNEL and CCSP, we looked more specifically at 
apoptosis in the CCSP+ airway epithelial cells where p52 is expressed. At 48 hours after LPS, a 
significant increase in the number of CCSP+TUNEL+ cells was detected in the airways of CCSP-p52 
mice compared to WT mice (Figure 24B, C). In the absence of LPS stimulation, no significant difference 
in apoptotic CCSP+ cells was observed in CCSP-p52 mice compared to WT (Figure 24B). To determine 
whether apoptosis was restricted to the p52 transgene-expressing CCSP+ airway epithelial cells, we 
evaluated apoptosis of type II alveolar epithelial cells by co-immunofluorescence staining of TUNEL and  
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Figure 22:  RelB expression does not augment effects of LPS stimulation in CCSP-
p52 mice.  
A) Quantitative real-time PCR for RelB expression in lungs of CCSP-p52 mice after control or RelB 
adenovirus delivery (n=3-4/group; p<0.05). B) Total BAL inflammatory cell numbers from WT and CCSP-
p52 mice after IT administration of Ad-RelB or Ad-Luc (n=3-8/group; *p<0.05 compared to WT). C) BAL 
inflammatory cell differentials from WT mice after IT administration of Ad-RelB or Ad-Luc (n=7-8/group; 
*p<0.05). Total (D) and differential (E) BAL inflammatory cell numbers from CCSP-p52 mice after Ad-RelB 
or Ad-Luc delivery with and without LPS stimulation for 48 hours (n=4/group; *p<0.05). 
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Figure 23:  p52 over-expression does not affect inflammatory cell recruitment or 
fibrosis after bleomycin.  
A) Total BAL inflammatory cell numbers, B) fibrosis scoring of lung sections, and C) representative lung 
photomicrographs (40x magnification) of fibrotic regions from WT and CCSP-p52 mice 3 weeks after 
bleomycin treatment (n=8-9 mice/group). 
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the type II cell-specific marker SPC. We found no differences in SPC+TUNEL+ type II cells between 
WT and CCSP-p52 mice after LPS (Figure 24D). Together, these data suggest that p52 directly regulates 
epithelial cell survival during conditions of inflammation or cellular stress.  
 
p52 over-expression in stressed epithelial cells leads to enhanced expression of pro-apoptotic 
factors 
To explore the mechanism by which p52 promotes apoptosis of epithelial cells, we used rat lung 
epithelial cells with stable p52 over-expression (designated RLE-p52), generated as described in Chapter 
3. To investigate whether p52 over-expression resulted in differential apoptosis in RLE-6TN cells, we 
first tested inflammatory stimuli (LPS, TNF-α, and IL-1β), but none of these treatments resulted in 
substantial apoptosis in empty vector control (designated RLE-EV) or p52 over-expressing cells, 
indicating that these cells are resistant to apoptosis in response to inflammatory stimuli. Next we 
evaluated the effect of ROS stimulation by treating cells with H2O2 (100 µM). At 24 hours after H2O2 
treatment, RLE-p52 cells demonstrated a significant decrease in cell viability compared to RLE-EV cells 
(Figure 25A). Increased apoptosis of RLE-p52 cells was supported by western blotting for cleaved 
caspase-3 at 18 hours of exposure to H2O2 (Figure 25B).  
In another model of acute cellular stress, serum starvation, we found that RLE-p52 cells had 
significantly reduced cell viability compared to RLE-EV cells as well as the parental cell line (designated 
RLE-WT) (Figure 25C). Similar to H2O2 treatment, we observed increased apoptosis of RLE-p52 cells by 
western blotting for cleaved caspase-3 after 18 hours of serum starvation (Figure 25D).To identify 
specific mediators of apoptosis differentially upregulated in RLE-p52 cells, we measured apoptotic 
factors in RLE-p52, RLE-EV, and RLE-WT cells after 18 hours of serum starvation using a quantitative 
real-time PCR apoptosis array. Compared to RLE-EV and RLE-WT cells, ten pro-apoptotic factors were 
significantly upregulated in RLE-p52 cells, including Bcl10, Bid, Bcl2l11 (Bim), Bok, caspase-4, 
caspase-6, caspase-7, Fas, Gadd45α, and Pycard (Figure 26A-J), suggesting that p52 plays a role in 
regulating expression of these genes in stressed cells and that these genes in turn promote apoptosis. 
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Figure 24:  p52 over-expression causes increased apoptosis of CCSP+ cells after in 
vivo LPS treatment.  
A) Quantification of TUNEL immunofluorescence staining (average number of TUNEL+ cells per high 
power field) performed on lung sections from WT and CCSP-p52 mice 24 and 48 hours after LPS (for 24 
hours n=3/group, for 48 hours n=6/group). B) Quantification of CCSP+TUNEL+ cells on whole lung 
sections from WT and CCSP-p52 mice on dox for 1 week (baseline) or 48 hours after LPS (n=5-8/group; 
**p<0.01). C) Representative confocal images of CCSP and TUNEL co-immunofluorescence staining of WT 
and CCSP-p52 lungs 48 hours after LPS (red=CCSP, green=TUNEL, blue=DAPI; 60x magnification). D) 
Quantification of SPC+TUNEL+ cells as a percentage of total TUNEL+ cells counted in ten 20x fields on 
lung sections from WT and CCSP-p52 mice 48 hours after LPS (n=4/group). 
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Figure 25:  p52 enhances apoptosis of lung epithelial cells during cellular stress in 
vitro.  
A) Survival of RLE-p52 and RLE-EV cells at 24 hours after H2O2 treatment (100 µM) measured by 
CellTiter-Glo (Promega). Percent survival was determined by normalizing values for each cell line treated 
with H2O2 to untreated values for each cell line (***p<0.001 comparing RLE-EV to RLE-p52). B) Pro-
caspase-3 and cleaved caspase-3 measured by western blotting of whole cell lysates from RLE-EV and RLE-
p52 with and without H2O2 stimulation. β-actin was used as a loading control. C) Survival of RLE-p52, RLE-
EV, and parental cell line RLE-WT after 12, 18, and 24 hours of serum starvation. Percent survival was 
determined by normalizing values for each cell line in medium lacking serum to values for each cell line in 
10% serum medium at each time point (18 hr **p<0.01 comparing RLE-EV to RLE-p52; 24 hr *p<0.05 
comparing RLE-p52 to RLE-EV and RLE-p52 to RLE-WT). D) Pro-caspase-3 and cleaved caspase-3 
measured by western blotting of whole cell lysates from RLE-WT, RLE-EV, and RLE-p52 cells grown in 
10% serum medium or after 18 hours of serum starvation.  
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Figure 26:  p52 regulates expression of apoptosis-associated genes during cellular 
stress.  
Quantitative real-time PCR analysis of Bcl10 (A), Bid (B), Bcl2l11 (C), Bok (D), Casp4 (E), Casp6 (F), 
Casp7 (G), Fas (H), Gadd45α (I), and Pycard (J) expression in RLE-WT, RLE-EV, and RLE-p52 cells after 
18 hours of serum starvation [n=4 biological replicates/group; *p<0.05, **p<0.01, ***p<0.001 p52 versus 
WT and EV]. 
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Discussion 
In these studies, we have identified an important and unexpected role for p52 in the airway 
epithelium in the setting of acute lung injury. In combination with LPS stimulation, p52 over-expression 
augmented epithelial apoptosis, enhanced lung inflammation without an increase in cytokine production, 
and enhanced lung injury and mortality. These effects appear to be driven directly by p52, since no 
changes in other NF-κB family members were observed after LPS stimulation and addition of RelB did 
not augment the phenotype. In addition, apoptosis of p52-expressing cells was specific to settings of acute 
cellular stress, since apoptosis was not observed in CCSP-p52 mice without LPS treatment or in RLE-p52 
cells under normal culture conditions. In patients with ARDS, increased nuclear p52 staining was 
observed in the airways and lung parenchyma, suggesting that p52 could impact lung injury. Taken 
together, our studies implicate p52 as a potential factor in determining ARDS severity through regulation 
of epithelial survival/apoptosis. 
Our findings, in conjunction with studies published by others, suggest that non-canonical and 
canonical NF-κB activation in the lung epithelium have different effects on inflammatory signaling and 
inflammatory cell recruitment. Over-expression of constitutively active IKKβ in the lung epithelium 
drives canonical NF-κB pathway activation causing a profound inflammatory response and elevated 
chemokine production (Cheng et al., 2007). In Chapter 3, we saw that over-expression of the non-
canonical pathway effector p52 did not cause inflammation on its own. Here, in the setting of LPS 
treatment, p52 over-expression led to increased inflammatory cell influx into the lungs, although it is 
likely that the inflammatory cell infiltrate is an indirect effect of epithelial cell death and altered barrier 
function. While other studies have suggested that p52 cooperates in regulating inflammatory cytokines in 
airway epithelial cells (Tully et al., 2012), we observed no differences in inflammatory cytokine 
production. In contrast, RelB over-expression led to increased inflammatory cell recruitment, which was 
not enhanced further by p52 over-expression. However, in the setting of LPS stimulation, we found that 
RelB over-expression did not augment lung inflammation and injury, indicating that p52 is the functional 
effector of the non-canonical NF-κB pathway in this model. In a different inflammatory context, RelB has 
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been shown to limit cigarette smoke-induced inflammatory cell recruitment and  cytokine production 
(McMillan et al., 2011). Collectively, these data imply that different NF-κB pathway components are 
uniquely involved in regulating lung epithelial inflammatory signaling, and their effects on inflammation 
may depend on the specific inflammatory signaling environment. 
The discovery that p52 over-expression promotes apoptosis of airway epithelial cells after LPS 
stimulation was unexpected, as many studies have suggested that p52 is pro-survival/proliferative. In 
fibroblasts, p52 and RelB protect against ROS-induced senescence by regulating CDK4 and CDK6 
expression and antagonizing p53 function (Iannetti et al., 2014), and in prostate cancer cells, p52 
promotes proliferation through regulation of cyclin D1 (Nadiminty et al., 2008). In vivo studies have 
demonstrated that expression of p100 in the mammary gland leads to hyperplasia (Connelly et al., 2007) 
and global p52 expression caused by deletion of the C-terminal inhibitory domain causes hyperplasia of 
the gastric epithelium (Ishikawa et al., 1997). In our studies, we found that p52 promoted epithelial cell 
apoptosis only in the context of acute cellular stressors, including LPS treatment in vivo. In contrast, we 
observed no differences in bleomycin-induced fibrosis in CCSP-p52 mice. In this model bleomycin 
causes direct DNA damage leading to cell-cycle arrest and apoptosis of airway and alveolar epithelial 
cells, followed by inflammation and fibrosis. Although it is possible that apoptosis of CCSP-expressing 
cells does not impact the degree of bleomycin-induced inflammation and fibrosis, the lack of phenotypic 
differences between CCSP-p52 mice and WT mice suggests that p52 may have a different functional role 
in this direct epithelial injury model compared to LPS treatment, which can induce epithelial cell death 
through extrinsic and intrinsic apoptosis pathways as well as activation of effector cells, particularly 
neutrophils (Neff et al., 2006). 
Interestingly, of the ten pro-apoptotic genes we identified with increased expression in p52 over-
expressing cells during serum starvation, nine are known to be regulated by NF-κB signaling (Bcl2l11, 
Casp4, Fas, and Pycard) or contain NF-κB consensus sequence binding sites in their promoters (Bcl10, 
Bid, Bok, Casp7, and Gadd45α), indicating that p52 may preferentially bind these gene promoters under 
conditions of cellular stress. Structurally, p52 lacks a transactivation domain, suggesting that interactions 
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with other NF-κB family members or transcriptional co-factors are necessary for regulation of target 
genes. In the setting of cellular stress, the pool of available NF-κB binding partners may be altered or 
additional transcriptional co-factor(s) that cooperate with p52 may be activated, affecting p52 binding site 
preferences. Additionally, epigenetic changes may occur as a result of stress signals that alter accessibility 
of regulatory regions of pro-apoptotic genes. Future studies are necessary to identify factors that modulate 
the transcriptional outcome of p52 activation in different contexts. 
Prior studies have demonstrated that LPS stimulation causes apoptosis of airway epithelial cells 
in murine models (Kawasaki et al., 2000; Vernooy et al., 2001), and our studies suggest that p52 
augments this apoptotic response. Although we cannot conclude that enhanced epithelial cell apoptosis is 
directly responsible for increased mortality of CCSP-p52 mice following LPS treatment, epithelial cell 
apoptosis has been shown to impact the degree of lung injury and survival of rodents after LPS 
administration (Kawasaki et al., 2000). Similarly, epithelial cell apoptosis is a prominent feature in the 
lungs of humans with ARDS (Albertine et al., 2002; Bardales et al., 1996; Galani et al., 2010; Guinee et 
al., 1996; Lee et al., 2008), and the degree of epithelial injury is an important factor predicting patient 
outcome (Albertine et al., 2002; Matthay and Wiener-Kronish, 1990). The identification of increased 
nuclear p52 in lungs of ARDS patients combined with the effects of p52 expression in the LPS model of 
ARDS/acute lung injury indicate that non-canonical NF-κB signaling could be an important factor in 
regulating epithelial cell survival/apoptosis, barrier integrity, and disease severity in patients with ARDS. 
Although more investigation is required to better understand the function of p52 in the setting of ARDS, 
our studies indicate that p52 interactions and/or target genes may serve as potential therapeutic targets for 
patients with ARDS.  
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CHAPTER V: 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
In vitro and xenograft models have indicated that canonical NF-κB signaling contributes to TKI-
resistance of EGFR-mutant tumors (Bivona et al., 2011; Blakely et al., 2015; De et al., 2014; Galvani et 
al., 2015), but our studies reveal that canonical NF-κB activation promotes both TKI-sensitive and TKI-
resistant EGFR-mediated lung cancer, suggesting a broader role for canonical NF-κB signaling in EGFR-
mediated tumorigenesis. Canonical NF-κB inhibition had no measureable effect on apoptosis of EGFR-
mutant cells. Instead, canonical pathway signaling was important for recruitment of inflammatory cells, 
namely tumor-promoting macrophages, suggesting that canonical NF-κB signaling contributes to lung 
carcinogenesis through paracrine signaling to the tumor microenvironment. These studies implicate 
canonical NF-κB as a key mediator of the intrinsic inflammatory response in EGFR-mutant tumors and 
suggest that therapeutic targeting of inflammatory cells, particularly macrophages, may be beneficial in 
patients with EGFR-mutant lung cancer. 
Increased expression of non-canonical pathway components have been observed in lung cancer 
(Dimitrakopoulos et al., 2012). Our findings suggest that p52 activation is a common phenomenon in lung 
adenocarcinoma and provide the first evidence of the functional involvement of non-canonical NF-κB 
signaling in lung carcinogenesis. In contrast to the role of canonical NF-κB signaling in lung tumors 
described above, non-canonical NF-κB activation enhanced proliferation of lung epithelial cells, leading 
to increased tumor number, enhanced tumor size, and more malignant tumors. While others have 
suggested that non-canonical NF-κB signaling can contribute to regulation of pro-inflammatory cytokines 
(Tully et al., 2012), no changes in inflammatory cell recruitment or inflammatory cytokine and 
chemokine production were observed as a result of p52 over-expression alone. In the context of the 
inflammatory stimulus LPS, p52 over-expression led to apoptosis of airway epithelial cells. Increased 
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macrophages and neutrophils were observed in the setting of p52 over-expression with LPS stimulation. 
However, this inflammatory influx was likely an indirect effect of the increased lung injury and altered 
barrier permeability caused by p52 over-expression, since concomitant changes in chemokine production 
were not measured. Increased p100/p52 expression was observed in the lungs of ARDS patients, 
implicating p52 in the pathogenesis of this disease. Together, these data suggest that non-canonical NF-
κB signaling functions primarily in a cell autonomous manner to regulate cell survival/apoptosis and 
proliferation. 
Overall, these studies indicate that both non-canonical and canonical NF-κB signaling in the lung 
epithelium contribute to carcinogenesis, functioning through different but complementary methods to 
promote tumors. While these findings extend our understanding on the role of canonical and non-
canonical NF-κB signaling in lung cancer, they also generate several important unanswered questions and 
suggest future experiments as discussed below. 
 
Canonical NF-κB Signaling as a Regulator of Pro-Tumorigenic Inflammatory Cell Recruitment 
 In Chapter 2, we show that canonical NF-κB inhibition has no measureable effect on survival of 
EGFR-mutant tumor cells, yet in other models of lung cancer, canonical NF- κB signaling has been 
suggested to promote cell survival. In mouse models of urethane-induced and KRAS-driven lung cancers, 
inhibition of canonical NF-κB increased apoptosis or reduced proliferation (Bassères et al., 2010; Meylan 
et al., 2009; Stathopoulos et al., 2007; Xia et al., 2012), although whether these findings are a direct or 
indirect effect of NF-κB inhibition is unclear. Supporting our findings, others have reported that canonical 
NF-κB inhibition did not affect proliferation of human lung cancer cell lines (Hopewell et al., 2013). Our 
studies do not rule out a role for canonical NF-κB signaling in the survival and proliferation of EGFR-
mutant lung tumors but suggest that cell-extrinsic signaling to recruit inflammatory cells may be a more 
important pro-tumor function of canonical NF-κB signaling in lung carcinogenesis. 
Although our studies suggest that epithelial canonical NF-κB signaling generates a tumor-
supportive inflammatory microenvironment, NF-κB-mediated paracrine signaling may not always 
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function in a pro-tumorigenic manner. Instead, canonical NF-κB signaling may be important for 
regulating the balance between a pro- and anti-tumor inflammatory microenvironment in lung cancer. 
Hopewell, et al. demonstrated that high levels of canonical NF-κB signaling in a murine lung cancer cell 
line led to recruitment of cytotoxic CD8+ T cells and reduced tumor burden (Hopewell et al., 2013), 
suggesting that canonical NF-κB activation could contribute to tumor rejection. In contrast, canonical NF-
κB signaling in the lung epithelium has also been shown to prevent tumor elimination by recruiting T 
regulatory cells, promoting T cell-mediated immune suppression through inhibition of cytotoxic CD8+ T 
cell recruitment (Zaynagetdinov et al., 2011b). Interestingly, in murine and human lung cancer cell lines, 
canonical NF-κB activation increases expression of both pro-tumor chemokines as well as anti-tumor 
chemokines, and in human tumors, expression of these NF-κB-regulated anti-tumor and pro-tumor 
chemokine profiles are mutually exclusive (Hopewell et al., 2013). Furthermore, this same study 
demonstrated that pro-tumor chemokine expression was significantly associated with poor overall 
survival of lung cancer patients, while high expression of chemokine genes involved in anti-tumor 
responses was associated with significantly improved survival, suggesting that canonical NF-κB signaling 
can have differential effects on the inflammatory microenvironment of lung tumors that could affect 
patient outcome. Whether canonical NF-κB signaling promotes pro- or anti-tumor immunity could be 
dependent on the oncogenic driver, the level of NF-κB activation, or microenvironmental stimuli that 
cause selective induction of different chemokine subsets, and studies to identify these factors could yield 
novel therapeutic targets that take advantage of canonical NF-κB activation in tumors to modulate pro-
tumor signaling to anti-tumor. Even though we did not observe differences in T cell numbers in our 
analysis, these studies also indicate that T cell recruitment is another important extrinsic function of 
canonical NF-κB signaling in lung tumors and suggest that the effect of T cell recruitment on tumors may 
depend on the ratio of the specific T cell populations in the tumor microenvironment.  
 
Therapeutic Targeting of Macrophages in Lung Cancer 
Our findings demonstrate that NF-κB-mediated inflammatory cell recruitment is important for 
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promoting EGFR-mutant lung tumors, suggesting that immunotherapeutic approaches, specifically those 
targeting macrophages, may be beneficial in patients with TKI-sensitive or TKI-resistant EGFR-mutant 
lung tumors. Because macrophages can promote tumors through a variety of mechanisms, a diverse array 
of strategies are being explored to therapeutically target them. The major approach has focused on 
preventing macrophage recruitment by inhibiting the MCP-1/CCL2 receptor or CSF1/M-CSF signaling 
(Noy and Pollard, 2014). However, in our studies, we did not measure significant differences in MCP-
1/CCL2 or CSF1/M-CSF, suggesting a different mediator may be the dominant macrophage chemotactic 
factor in our model. Whether these inhibitors would reduce macrophage recruitment and consequently 
tumor burden in EGFR-driven pre-clinical models or in patients with EGFR-mutant lung cancer is 
unclear. Future studies to identify the NF-κB-regulated mechanism of macrophage recruitment in the 
EGFRL858R and EGFRL/T lung cancer models may identify novel therapeutic targets.  
Therapies that target macrophage function or shift macrophage polarization, rather than their 
recruitment, could also be effective patients with EGFR-mutant lung cancers. Macrophages are an 
important producer of vascular endothelial growth factor (VEGF), which promotes high density 
angiogenesis and vessel leakiness in tumors. Depletion of alveolar macrophages reduces VEGF levels and 
therefore angiogenesis and tumor burden in a model of chemical carcinogen-induced lung tumorigenesis 
(Zaynagetdinov et al., 2011a), and bevacizumab, a VEGF monoclonal antibody, has been approved for 
treatment of NSCLC patients (Sandler et al., 2006). Macrophages can also directly suppress T cell 
proliferation and cytotoxic T cell function by expressing the PD-L1 or B7 ligands for the T cell receptors 
PD-1 or CTLA-4 receptors, respectively (Kuang et al., 2009; Linsley et al., 1994), and therapies targeting 
these interactions have already been approved for patients with NSCLC. IL-4 production by CD4+ T cells 
and tumor cells can induce an immunosuppressive, pro-tumor phenotype in macrophages (Coussens et al., 
2013; DeNardo et al., 2009; Gocheva et al., 2010), and antagonist αIL-4 antibodies reprogram tumor-
associated M2 macrophages, as well as other immunosuppressive immune cell types, toward an M1 
phenotype in mammary cancer (DeNardo et al., 2009). Future studies to investigate the specific 
mechanism(s) by which macrophages promote EGFR-mediated lung tumorigenesis in our pre-clinical 
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models will provide valuable evidence regarding whether these therapies may benefit patients with EGFR 
mutations in their tumors.  
 
Non-canonical NF-κB Signaling as a Regulator of Cell Survival/Proliferation and Apoptosis 
A number of studies by others have suggested that non-canonical NF-κB signaling promotes cell 
survival/proliferation in a variety of cell types, including cancer cells (Connelly et al., 2007; Cormier et 
al., 2013; De Donatis et al., 2015; Iannetti et al., 2014; Ishikawa et al., 1997; Nadiminty et al., 2008), 
supporting our findings in urethane-induced lung cancer. However, our results extend the role of p52 to 
the promotion of apoptosis in certain contexts, suggesting that the net effect of non-canonical NF-κB 
activation may be dependent on the specific nature or level of cellular stress. The particular cell type may 
also influence the consequence of non-canonical NF-κB activation. Future studies employing SPC-rtTA 
mice (Perl et al., 2002) to drive p52 over-expression in type II pneumocytes would be useful for 
determining whether p52-induced proliferation after urethane and apoptosis after LPS are conserved 
mechanisms in lung epithelial cells. p52 likely promotes proliferation/apoptosis through changes in 
transcriptional regulation, since p52 over-expression led to increased mRNA levels of proliferative and 
apoptotic factors. Differential availability of other NF-κB family members or activation of transcriptional 
co-factors may modify p52 binding site preferences in different contexts. Additionally, epigenetic 
changes could occur that alter the availability of gene regulatory regions, thus affecting p52-mediated 
transcription. Studies to elucidate the contextual modifiers that affect p52 transcription could identify 
novel therapeutic targets, as modulation of these factors could potentially convert the pro-proliferative 
effect of p52 in the context of lung cancer to a pro-apoptotic effect.  
One potential cofactor that could be involved in modifying p52 transcription is p53. The p53 
transcription factor regulates transcriptional responses to cell cycle checkpoint engagement, DNA 
damage, and environmental stress, and in tumors, functions as a tumor suppressor. p53 can recruit p52 to 
promoters of p53 target genes to modulate their expression (Schumm et al., 2006), but the outcome of this 
p52-p53 crosstalk may depend on the relative levels of activation of each pathway. p52 cooperates with 
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p53 to promote expression of pro-apoptotic genes in cells with inducible p53 expression and in the 
context of UV-induced DNA damage, which strongly activates p53 (Schumm et al., 2006). In contrast, in 
a setting with lower levels of p53 activation, p52 has been shown to prevent ROS-induced senescence by 
antagonizing expression of p53-regulated genes (Iannetti et al., 2014). In the setting of an acute cellular 
stressor such as serum starvation or high-dose LPS, high levels of p53 activation may dominate the 
response and p52 may work together with p53 to promote apoptosis. Conversely, in lung cancer, high 
levels of p52 may enable p52 to overcome the effects of oncogene-mediated p53 activation, promoting 
proliferation of tumor cells. In addition to increased tumor burden, we observed enhanced malignant 
progression of lung tumors in CCSP-p52 mice. p53 is mutated in 50-70% of lung adenocarcinoma tumors 
(Herbst et al., 2008), and studies in genetic models of KRAS-induced lung tumorigenesis suggest that 
suppression of p53 activation is required for tumors to progress from adenomas to more malignant tumor 
stages (Feldser et al., 2010; Junttila et al., 2010). Our data suggest that non-canonical NF-κB and 
specifically p52 activation could be a mechanism enabling malignant progression of tumors retaining 
wild-type p53. 
A second candidate cofactor that could affect p52 transcription is Bcl-3, an atypical member of 
the IκB family. Bcl-3 forms a complex with p52 homodimers to regulate gene transcription (Bours et al., 
1993). Specifically, p52/Bcl-3 complexes have been shown to promote transcription of cyclin D1 (Rocha 
et al., 2003; Wang et al., 2010), but these complexes can also inhibit target gene transcription. Whether 
p52/Bcl-3 complexes cause transcriptional activation or repression may depend on the concentration and 
phosphorylation status of Bcl-3 (Bundy et al., 1997). Little is known about the role of Bcl-3 in epithelial 
cells during lung inflammation and carcinogenesis, so studies investigating Bcl-3 in these settings may 
provide further insight into p52 function and gene transcription. 
 Epigenetic factors could also modify the transcriptional landscape of the cell, affecting the 
transcriptional outcome of p52 activation in different contexts. p52 has been shown to recruit and, in 
some cases, directly interact with epigenetic modifiers, including histone acetyl transferases (HATs) p300 
and cyclic-AMP response element binding protein (CBP) and histone deacetylase (HDAC) 1, HDAC2, 
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and HDAC4. Histone acetylation relaxes the interactions between the histone molecule and DNA, making 
DNA more accessible for transcription factor binding. In the placenta, binding of RelB and p52 enabled 
CBP recruitment and target gene transcription (Stefano et al., 2015). p52 can also recruit p300 to gene 
promoters, including the promoters of pro-apoptotic factors DR5 and PUMA, resulting in increased 
transcription (Nadiminty et al., 2010; Schumm et al., 2006). Conversely, histone deacetylation condenses 
the chromatin structure, repressing transcription. After UV stimulation, p52-HDAC1 complexes inhibit 
cyclin D1 transcription (Rocha et al., 2003). In multiple myeloma, a complex consisting of p52, RelB, 
and HDAC4 maintains repressive chromatin around pro-apoptotic genes Bim and BMF, and this complex 
was necessary for cell survival and tumor growth (Vallabhapurapu et al., 2015). In some instances both 
HAT and HDAC proteins are simultaneously recruited to promoters by p52 (Schumm et al., 2006; 
Stefano et al., 2015), suggesting that p52 may play a role in regulating the balance of histone acetylation 
and the activation state of chromatin. Adding another layer of complexity, HAT and HDAC proteins can 
also directly modify transcription factors such as p53 and NF-κB, although the effect of this modification 
on p52 remains unclear (Deng et al., 2006; Hu and Colburn, 2005). In lung cancer, increased expression 
of HDAC1 is associated with more advanced tumors and correlates with poor prognosis (Minamiya et al., 
2011; Sasaki et al., 2004), and HDAC inhibitors have been proposed as therapies for patients with lung 
cancer (Neal and Sequist, 2012). Future studies to understand the interactions between non-canonical NF-
κB signaling, HATs, and HDACs could identify novel therapeutic options for patients with p52 activation 
in their tumors. 
Crosstalk between Canonical and Non-canonical NF-κB Signaling Pathways 
While the paradigm of distinct canonical and non-canonical NF-κB signaling pathways is useful 
for thinking about NF-κB signaling, numerous studies suggest that extensive crosstalk occurs between 
these pathways, indicating that NF-κB signaling is likely much more complex physiologically. The 
canonical pathway can induce non-canonical pathway activation transcriptionally through regulation of 
the Nfkb2 and Relb genes by p65/p50 heterodimers (Bren et al., 2001; Lombardi et al., 1995). The non-
canonical pathway can also inhibit the canonical pathway through the C-terminal domain of p100, also 
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known as IκBδ (Shih et al., 2009), forming a negative feedback loop. Mice expressing a mutant form of 
p100 that is unable to undergo proteolytic processing show reduced activation of p65-containing dimers 
(Tucker et al., 2007), suggesting that IκBδ may sequester the canonical pathway heterodimer in the 
absence of IKKα activation (Shih et al., 2009). Activation of non-canonical pathway signaling can then 
lead to canonical pathway signaling through proteolytic processing of the C-terminal domain of p100, 
freeing bound p65/p50 (Basak et al., 2007).  
Dimerization of NF-κB family members is more extensive than represented by the traditional 
p65/p50 and Relb/p52 heterodimers associated with canonical and non-canonical NF-κB signaling. In 
lymphoblastoid B cells, eleven different dimer combinations have been observed (Zhao et al., 2014). 
Different dimer combinations may have specific binding site affinities dictated by DNA sequence 
variations as small as a single nucleotide, affecting target gene transcription (Bonizzi et al., 2004; Fusco 
et al., 2009; Kunsch et al., 1992; Leung et al., 2004; Siggers et al., 2011), and dimers containing p52 may 
be recruited more frequently to atypical binding sites that lack a κB consensus sequence (Zhao et al., 
2014). Many NF-κB target genes have multiple κB sites in their promoters, and gene expression analysis 
of lymphotoxin β-stimulated mouse embryonic fibroblasts revealed that the majority of induced genes 
require both p65- and RelB-containing dimers (Lovas et al., 2008), suggesting that transcriptional 
regulation may involve an interplay of different dimers at several sites in gene promoters. However, the 
differential specificity of NF-κB family members is not solely determined by DNA-protein interactions 
but may also be influenced by other transcription factors (Hoffmann et al., 2003; Wang et al., 2007; Zhao 
et al., 2014). Upon binding to specific κB sites, dimer pairs may adopt distinct DNA sequence-dependent 
conformations that are differentially recognized by other transcriptional cofactors (Chen-Park et al., 2002; 
Leung et al., 2004). In addition, chromatin configuration can control the steric accessibility of binding 
sites for different dimers (Saccani et al., 2001). 
While the studies described here demonstrate that both canonical and non-canonical NF-κB 
signaling contribute to lung carcinogenesis, our understanding of how interactions between these 
pathways affect lung cancer is limited. The lack of therapeutic efficacy of canonical NF-κB inhibitors in 
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cancer patients, as discussed below, also suggests that a better understanding of crosstalk between these 
pathways may improve current treatment strategies. Using currently available mouse models, in vivo 
studies could be performed to explore the effect of p52 over-expression in the absence of canonical 
pathway activation by crossing DN-IκB mice to CCSP-p52 mice. CCSP-p52 mice could also be 
combined with p65 conditional knockout mice to determine the impact of p52 over-expression 
specifically in the absence of p65 (Steinbrecher et al., 2008). Additional in vitro studies knocking out 
combinations of NF-κB family members in cancer cell lines or in conjunction with inflammatory and cell 
stress stimuli would also enable a detailed analysis of the contributions of each family member in 
different contexts. Future studies using in vivo and in vitro models to examine the interactions between 
the canonical and non-canonical NF-κB signaling pathways in different contexts is necessary to fully 
understand how NF-κB influences cell survival/proliferation and apoptosis to impact tumorigenesis. 
 
Therapeutic Targeting of NF-κB Signaling in Lung Cancer 
 A variety of studies have implicated canonical NF-κB signaling as a key regulator of human 
cancer and inflammatory disease. Consequently, much interest has centered on developing drugs to 
inhibit canonical NF-κB signaling. Global inhibition of canonical NF-κB signaling has shown therapeutic 
benefit in some pre-clinical models of lung cancer, with the major strategies focusing on IKKβ or 
proteasome inhibition, which prevents IκBα degradation. Treatment with the proteasome inhibitor 
bortezomib, BAY-117082 (a compound which prevents IκBα phosphorylation (Pierce et al., 1997)), and 
Compound A (a specific IKKβ inhibitor (Ziegelbauer et al., 2005)) have all reduced lung tumor burden in 
short term in vivo studies (Bassères et al., 2014; Karabela et al., 2012; Xue et al., 2011). However, despite 
evidence from in vivo models, including our own studies here, suggesting that canonical NF-κB inhibition 
inhibits lung carcinogenesis, no therapeutic benefit has been observed in clinical trials thus far (Besse et 
al., 2012; Fanucchi et al., 2006). Correspondingly, long term treatment with bortezomib in pre-clinical 
models of lung cancer led to resistance and, in one study, actually enhanced tumor formation (Karabela et 
al., 2012; Xue et al., 2011). In vivo studies also suggest that global IKKβ inhibition could have 
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undesirable and even detrimental side effects, since signaling through IKKβ is important for gut, skin, and 
liver homeostasis (Pasparakis, 2009) and inhibition of IKKβ can actually increase IL-1β secretion by 
myeloid cells (Greten et al., 2007), suggesting that global inhibition of canonical NF-κB signaling at least 
by these methods may not be the optimal therapeutic strategy for lung cancer patients. 
 Our findings provide a basis for investigations into targeting the non-canonical NF-κB pathway 
as a novel therapeutic approach in lung cancer. In Chapter 3, our in vivo studies suggested that non-
canonical NF-κB activation can promote tumor growth and progression, and analysis of p100/p52 
expression in human lung tumor samples suggested that this pathway is active in a large proportion of 
lung cancer patients. Non-canonical NF-κB signaling has also been shown to compensate for canonical 
pathway inhibition in diffuse large B cell lymphomas treated with IKKβ inhibitors, indicating that non-
canonical pathway activation could limit the therapeutic efficacy of treatment with canonical pathway 
inhibitors (Lam et al., 2008). 
 Rational therapeutic strategies for targeting non-canonical NF-κB signaling include inhibition of 
NIK or IKKα, both key regulators of non-canonical NF-κB signaling. However, few specific inhibitors 
have been described for these kinases. Currently available IKK inhibitors either function as pan-IKK 
inhibitors or preferentially target IKKβ, but no selective IKKα inhibitors have been described. While 
selective NIK inhibitors have been identified, most are only effective in vitro due to their poor 
pharmacokinetic properties. Still, NIK-specific inhibitors induce apoptosis of multiple myeloma cell lines 
in vitro (Demchenko et al., 2014), suggesting that further development of these inhibitors to improve their 
functionality in vivo could be beneficial. Additionally, while non-canonical pathway inhibition could have 
a therapeutic effect on its own, specific inhibition of non-canonical NF-κB might also allow lower doses 
of IKKβ inhibitors to achieve comparable blockade of the canonical NF-κB pathway, potentially 
minimizing the undesirable side effects of IKKβ inhibition (Lam et al., 2008). Other strategies for 
inhibiting non-canonical NF-κB signaling include membrane-permeable peptides that inhibit nuclear 
translocation of RelB/p52 and targeting of upstream signaling mediators, such as TNFR-associated 
factors (TRAFs) and receptor interacting proteins (RIPs) (Storz, 2013; Xu et al., 2008). 
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 The studies described here identify important functions of NF-κB signaling in lung tumors that 
could be exploited as indirect or downstream therapeutic targets, bypassing the unwanted side effects of 
and circumventing the need for specific NF-κB inhibitors. Our studies in Chapter 2 identified macrophage 
recruitment as a critical factor regulated by canonical NF-κB signaling that could be therapeutically 
targeted through a variety of mechanisms as discussed above. In Chapter 3, we identified a network of 
non-canonical pathway-associated genes that could potentially serve as indirect therapeutic targets in 
tumors with non-canonical pathway activation. In this network, several of the nodes (defined as having 4 
or more connections) have targeted therapies currently in development for clinical use, including aurora 
kinase B (AURKB), CDK1, polo-like kinase 1 (PLK1) (Chopra et al., 2010; Kollareddy et al., 2012; 
Lapenna and Giordano, 2009), suggesting that these therapies may be beneficial for hindering the tumor-
promoting effect of non-canonical pathway activation in lung cancer. As discussed above, studies to 
identify factors that can convert the pro-proliferative role of non-canonical NF-κB signaling in tumors to 
the pro-apoptotic effect observed in studies of acute cellular stress in Chapter 4 could also identify novel 
therapeutic targets to modulate non-canonical NF-κB signaling. Additionally, combined strategies 
targeting canonical and/or non-canonical signaling in conjunction with TKIs may be beneficial for 
patients with lung cancer, particularly since canonical NF-κB signaling has been proposed as a 
mechanism of therapeutic resistance to several EGFR inhibitors (Bivona et al., 2011; Galvani et al., 
2015). 
 
Concluding Remarks 
The studies here demonstrate that both canonical and non-canonical NF-κB signaling can 
promote lung tumors and provide new insights into their mechanistic functions during carcinogenesis. 
Importantly, the complexities of canonical and non-canonical NF-κB signaling indicate that the 
consequences of pathway activation, as well as inhibition, can be dependent on the specific cell type and 
context. These studies advance our understanding of lung tumor development and progression as well as 
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NF-κB signaling in cancer and inflammation, while pointing toward new therapies for lung cancer 
patients that should be tested in preclinical models.  
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